Protocol 331 -201-00242
2
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul2020Trial Conduct for COVID -
19
All procedures and assessments in this protocol are to be followed to the fullest 
extent possible. The sponsor, in coordination with the site, investigator(s), and 
medical monitor, will continuously monitor and evaluate the benefits and risks to 
subject participation in the clinical trial as it related to COVID -19. If any protocol -
specified activities were not able to be performed, or cannot be performed due to 
COVID -19 considerations, refer to the COVID -19 Addendum for the appropriate 
measures to be followed. Appropriate measures may include replacing in -person 
visits with remote or virtual visits (phone or video) as deemed necessary by the 
investigator to ensure subject safety and maintain protocol requirements.
Table of Contents
Table of Contents ........................................................................................... 3
List of In-text Tables ..................................................................................... 9
List of In-text Figures .................................................................................. 10
1 Protocol Summary .............................................................................. 11
1.1 Synopsis.............................................................................................................11
1.2 Schema ..............................................................................................................16
1.3 Schedule of Assessments ................................ ................................ ................... 17
2 Introduction ........................................................................................ 22
2.1 Trial Rationale ...................................................................................................22
2.2 Background .......................................................................................................23
2.3 Known and Potential Risks and Benefits ..........................................................24
3 Objectives and Endpoints ................................
.................................. 25
4 Trial Design ......................................................................................... 26
4.1 Type/Design of Trial .........................................................................................26
4.2 Scientific Rationale for Trial Design .................................................................27
4.3 Dosing Rationale ...............................................................................................28
4.4 End of Trial Definition ......................................................................................28
4.5 Definition of Completed Subjects .....................................................................28
5 Trial Population ...............................................................
................... 29
5.1 Subject Selection and Numbering .....................................................................29
5.2 Eligibility  Criteria
................................ ................................ .............................. 29
5.2.1 Inclusion Criteria ................................ ................................ ............................ 29
5.2.2 Exclusion Criteria ...........................................................................................30
5.3 Lifesty le Considerations ................................ ................................ .................... 34
5.3.1 Meals and Dietary  Restrictions ................................ ................................ .......34
5.3.2 Caffeine, Alcohol, and Tobacco .....................................................................34
5.3.3 Activity ................................ ................................ ................................ ........... 34
5.4 Screen Failures ................................ ................................ ................................ ..34
6 Trial Treatments ................................................................................. 35
Protocol 331 -201-00242
4
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul20206.1 Trial Treatments Administered .........................................................................35
6.1.1 Medical Devices .............................................................................................36
6.2 Management of Investigational Medicinal Product ..........................................36
6.2.1 Packaging and Labeling ..................................................................................36
6.2.2 Storage ............................................................................................................36
6.2.3 Accountability .................................................................................................36
6.2.4
Returns and Destruction .................................................................................37
6.2.5 Reporting of Product Quality  Complaints ......................................................37
6.2.5.1
Eliciting and Reporting Product Quality  Complaints .................................37
6.2.5.2 Information Required for Reporting Purposes ............................................38
6.2.5.3 Return Process .............................................................................................38
6.2.5.4 Assessment/Evaluation ...............................................................................38
6.3 Measures to Minimize/Avoid Bias ....................................................................38
6.4 Subject Compliance ...........................................................................................39
6.5 Concomitant Medications or Therapies ............................................................39
6.5.1
Prohibited Medications...................................................................................39
6.5.2 Benzodiazepine Use During the Trial.............................................................42
6.5.3 Permitted Medications ....................................................................................42
6.5.4 Rescue Medications ........................................................................................42
6.6 Intervention after the End of the Trial ...............................................................43
7 Stopping Rules, Withdrawal Criteria, and Procedures .................. 43
7.1 Entire Trial or Treatment ...................................................................................43
7.2 Individual Site ...................................................................................................43
7.3
Individual Subject Discontinuation................................ ................................ ...43
7.3.1 Treatment Interruption ................................ ................................ .................... 43
7.3.2 Treatment Discontinuation .............................................................................43
7.3.3 Documenting Reasons for Treatment Interruption or Discontinuation ..........44
7.3.4 Withdrawal of Consent ...................................................................................44
7.3.5
Procedures to Encourage Continued Trial Participation ................................ 45
7.4 Definition of Subjects L ost to Follow -up................................ .......................... 46
8 Trial Procedures ................................................................................. 46
8.1 Efficacy  Assessments........................................................................................46
Protocol 331 -201-00242
5
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul20208.1.1
Clinician Administered...................................................................................46
8.1.1.1
Zanarini Rating Scale for Borderline Personalit y Disorder ........................46
8.1.1.2 Clinical Global I mpression -Severit y of Illness Scale .................................47
8.1.1.3 Clinical Global I mpression -
Improvement Scale .........................................47
8.1.2 Patient Completed ...........................................................................................48
8.1.2.1 Patient’s Global I mpression -Severit y
.......................................................48
8.1.2.2 Patient’s Global I mpression -Change ........................................................48
8.1.3 Screening Assessments ...................................................................................48
8.1.3.1 Structured Clinical Interview for DSM -5 Personality  Disorders ................48
8.1.3.2 Mini I nternational Neuropsy chiatric Interview for Psy chotic 
Disorders ................................ ................................ ................................ .....49
8.2 Pharmacokine tic Assessments ...........................................................................49
8.2.1 Pharmacokinetic Blood Samples ....................................................................49
8.3 Pharmacod ynamic Assessments ........................................................................49
8.5 Biomarker Assessments ................................ ................................ .................... 50
8.7 Safety  Assessments ................................ ................................ ........................... 51
8.7.1 Clinical L aboratory  Assessments ...................................................................51
8.7.2 Physical Examination ................................ ................................ ..................... 52
8.7.3 Vital Signs ................................ ................................ ................................ ......53
8.7.4 Electrocardiogram ...........................................................................................54
8.7.5 Suicidality  Monitoring 
-Columbia -Suicide Severity  Rating Scale ................55
8.7.6 Other Safet y Variables ....................................................................................55
8.7.6.1 Simpson Angus Scale ................................ ................................ .................. 55
8.7.6.2 Abnormal Involuntary  Movement Scale ................................ ..................... 56
8.7.6.3 Barnes Akathisia Rating Scale................................ ................................ ....56

Protocol 331 -201-00242
6
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul20208.8 Adverse Events ..................................................................................................57
8.8.1
Definitions ......................................................................................................57
8.8.2
Eliciting and Reporting Adverse Events.........................................................59
8.8.3 Immediately
 Reportable Events ......................................................................59
8.8.4 Medical Device Incidents (Including Malfunctions) ......................................60
8.8.5 Adverse Events of Special I
nterest .................................................................60
8.8.6 Potential Serious Hepatotoxicity ....................................................................60
8.8.7 Procedure for Breaking the Blind ...................................................................60
8.8.8 Follow -up of Adverse Events .........................................................................60
8.8.8.1 Follow -up of Nonserious Adverse Events ..................................................60
8.8.8.2 Follow -up of Immediately  Reportable Events ............................................61
8.8.8.3 Follow -up and Reporting of I mmediatel y Reportable Events
Occurring After Last Scheduled Contact ....................................................61
8.9 Treatment of Overdose ......................................................................................62
8.10 Subject Assessment Recording .........................................................................62
8.11 Other Assessments ............................................................................................62
9 Statisti cal Considerations ...............................................................
...62
9.1 Sample Size .......................................................................................................62
9.2 Datasets for Anal ysis.........................................................................................62
9.3 Handling of Missing Data for Primary  and Key  Secondary  Endpoint 
Anal ysis.............................................................................................................62
9.4 Statistical Analy ses............................................................................................63
9.4.1 Efficacy  Anal yses...........................................................................................63
9.4.1.1 Primary  Efficacy  Endpoint Analy sis...........................................................63
9.4.1.2 Key Secondary  Efficacy  Endpoint Analy sis...............................................63
9.4.1.3 Secondary  Efficacy  Endpoint Analy sis................................ ....................... 63
9.4.1.4 Control of Experiment -wise Type 1 Error ................................ .................. 63
9.4.2 Safety  Anal ysis...............................................................................................63
9.4.2.1 Adverse Events ................................ ................................ ............................ 64
9.4.2.2 Clinical L aboratory  Data ................................ ................................ ............. 64
9.4.2.3 Physical Examination and Vital Signs Data ................................ ................ 64
9.4.2.4 Electrocardiogram Data ..............................................................................64

Protocol 331 -201-00242
7
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul20209.4.2.5 Other Safet y Data ........................................................................................65
9.4.3.1 Analy sis of Demographic and Baseline Characteristics .............................65
9.4.3.2 Pharmacokinetic Analy sis...........................................................................65
9.4.3.3 Pharmacod ynamic Anal ysis........................................................................65
9.4.3.4 Pharmacokinetic/Pharmacody namic Anal ysis............................................65
9.5 Interim Anal ysis and Adaptive Design ................................ ............................. 66
9.5.1 Data Monitoring Committee ...........................................................................66
10 Supporting Documentation and Operational Considerations .......67
10.1 Appendix 1: Regulatory , Ethical, and Trial Oversight Considerations ............. 67
10.1.1 Ethics and Responsibility ...............................................................................67
10.1.2 Informed Consent ...........................................................................................67
10.1.3 Confidentiality ................................................................................................68
10.1.4 Quality  Control and Quality  Assurance ..........................................................69
10.1.4.1 Monitoring ..................................................................................................69
10.1.4.2 Auditing ......................................................................................................69
10.1.5 Protocol Deviations ........................................................................................69
10.1.6 Records Management .....................................................................................70
10.1.6.1 Source Documents ......................................................................................70
10.1.6.2 Data Collection ............................................................................................70
10.1.6.3 File Management at the Trial Site ...............................................................71
10.1.6.4 Records Retention at the Trial Site .............................................................72
10.1.6.5 Publication Authorship Requirements ........................................................72
10.2 Appendix 2: Clinical L aboratory  Tests .............................................................74
10.3 Appendix 3: Contraceptive Guidance and Collection of Pregnancy  
Information ........................................................................................................75
10.4
Appendix 4: Abbreviations ................................ ................................ ............... 77
10.5 Appendix 5: Criteria for Identify ing Laboratory Values of Potential 
Clinical Relevance .............................................................................................80
10.6 Appendix 6: Criteria for Identify ing Vital Signs of Potential Clinical 
Relevance ..........................................................................................................81

Protocol 331 -201-00242
8
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul202010.7 Appendix 7: Criteria for Identify
ing ECG Measurements of Potential 
Clinical Relevance .............................................................................................82
10.8 Appendix 8: Protocol Amendments ..................................................................83
11 References ...............................................................
............................. 86

Protocol 331 -201-00242
9
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul2020List of In
-text Tables
Table 1.3-1 Schedule of Assessments ................................ .............................. 17
Table 3-1 Trial Objectives and Endpoints ..................................................... 25
Table 6.5
-1 List of Medications Prohibited Before the Trial ........................... 40
Table 6.5-2 List of Medications Prohibited During the Trial ........................... 41
Protocol 331 -201-00242
10
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul2020List of In
-text Figures
Figure 1.2 -1 Trial Design Schematic ................................................................. 16
Protocol 331 -201-00242
11
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul20201 Protocol Summary
1.1 Synopsis
Name of Sponsor: Otsuka Pharmaceutical Development & Commercialization, I nc.
Name of Investigational Medicinal Product: Brexpiprazole (OPC -
34712)
Protocol No.: 331-201- 00242
IND No.: 141091
Protocol Title :A Multicenter, Randomized, Flexible -dose, Double -blind Trial of 
Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality  
Disorder
Protocol Lay Person Short Title :
A Trial of Brexpiprazole in the Treatment of Borderline Personalit y Disorder
Clinical Phase/Trial Type: Phase 2 / Therapeutic confirmatory
Treatment/Indication: For the treatment of borderline personality  disorder (BPD)
Objectives and Endpoints:
Trial Objectives and Endpoints
Objectives Endpoints
Primary : To compare the efficacy  of 
brexpiprazole versus placebo for the 
treatment of subjects with a diagnosis of 
BPDPrimary  efficacy : Change from baseline 
in the ZAN -BPD total score
Key secondary  efficacy : Change from 
baseline in the CGI -Sscore
Secondary  efficacy :
Change from baseline in the PGI -S
for each trial visit during the double-
blind treatment period
PGI-Cscore
CGI-Iscore

Protocol 331 -201-00242
13
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul2020The trial will consist of a screening period (up to 21 days), a 12-week, double -blind 
treatm ent period, and safety  follow -up (21 [± 2] day s after the last dose of investigational 
medicinal product [I MP]).
Trial Population:
Approximately  350 subjects will be screened to have 240 subjects randomized into the 
trial. 
Key Inclusion Criteria:
The trial population will consist of male and female outpatients, a ged 18 to 65 y ears, 
inclusive. Subjects will have a BPD diagnosis according to Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition (DSM -5) and confirmed b y a v alid diagnostic 
instrument ( Structured Clinical I nterview for DSM -5 Personality  Disorders 
[SCI D-5- PD]) and a total score of ≥ 12 on the Zanarini Rating Scale for Borderline 
Personality  Disorder ( ZAN -BPD ) at the screenin g visit and at Day 0 . In addition, a score 
of ≥ 2in at least 2 of the following 4 ZAN -BPD subscale items will be required at 
screening and Day  0: 1) “inappropriate, intense anger or difficulty  controlling anger” 
(hereafter referred to as inappropria te ang er), 2)
“transient stress- related paranoid 
ideation or severe dissociative sy mptoms” (paranoid ideation), 3) “affective instability  
due to a marked reactivity of mood” ( affective instability ), and 4) “impulsivity  in at least 
other two areas that are potentially  self-damaging” (impulsivity ).
Trial Sites
:
This trial will be conducted in the United States (US) and Europe.
Inve stigational Medicinal Product , Dose, Dosage R egimen, Treatment Duration, 
Formulation, Mode of Administration:
During the double -blind treatment period, subjects will receive I MP, consisting of up to 
3mg/day  brexpiprazole or placebo, depending on the subject’s treatment assignment.
All doses of IMP should be taken at the same time each day , if possible. All doses of IMP 
can be taken without regard to meals. If tolerability issues arise, the timing of 
administration of the I MP may  be adjusted at the investigator’s discretion in order to 
achieve optimum tolerability  and compliance.
Trial Assessments:
Assessments for Efficacy: ZAN -BPD , Clinical Global I mpression -Severity (CGI -S), 
Clinical Global I mpression -Improvement (CGI -I), Patient’s Global I mpression of Change 
(PGI -C), Patient’s Global Impression of Severit y (PGI -S), 

Protocol 331 -201-00242
14
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul2020 
 
Assessments for Pharmacokinetics: blood sampling for IMP plasma concentrations.
 
 
 
.
Assessments for Safet y: AE, clinical laboratory  tests (hematology , serum chemistry  
[including glycosylated hemoglobin (HbA1c) , thyroid- stimulating hormone (TSH), and 
blinded prolactin ], and urinaly sis), electrocardiogram ( ECG ), vital s igns, phy sical 
examination findings, Columbia -Suicide Severity  Rating Scale (C -SSRS) , Simpson 
Angus Scale (SAS) , Abnormal Involuntary  Movement Scale (AIMS) , and Barne s 
Akathisia Rating Scale (BARS)
.
Screening/Other: SCID-5- PD, Mini I nternational Neurops ychiatric Interview (MINI) for 
Psychotic Disorders , medical history , psychiatric history  (including BPD history and 
BPD therap y),urine drug screen/blood alcohol test, and urine pregnancy  test.
Data Monitoring Committee: No ne
Statistical Methods:
In general , descriptive statistics will be provided for all efficacy  and safety  endpoints. 
Continuous variables will be summarized by  tabulations of mean, median, range, and 
standard deviation (SD). Tabulations of frequency distributions will be provided for 
categoric al variables. The change from baseline in the ZAN -BPD total score will be 
analyzed using a mixed- effect model repeated measures (MMRM) methodology  with the 
unstructured variance covariance matrix. The model will include fixed class -effect terms 
for treatme nt, trial center, visit week, and an interaction term of treatment by  visit week 
and include the interaction term of baseline values of ZAN -BPD total score by  visit week 
as a covariate. Other continuous efficacy  endpoints will also be anal yzed using MMRM 
methodology . 
 

Protocol 331 -201-00242
15
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul2020Trial Duration:
Each subject in this trial is expected to participate in the following perio ds of the trial 
(approximate durations listed):
Eligibility  screening period ( up to 21 days)
Double
-blind randomized t reatment period ( 12weeks)
Post-treatment safet y follow -up period ( 21days; for subjects who do not enroll in the 
open -label extension trial)
Overall, the trial duration from first informed consent form signed to the final subject 
assessment is expected to be approximately  15.5 months.
Protocol 331 -201-00242
16
Confidential -Proprietary Information Original Approval: 09 Jul 20191.2 Schema
ADT = anti depressant therapy; BPD = borderline personality disorder; ZAN -BPD =Zanarini Rating Scale for Borderline Personality Disorder.
aFor subjects who do not enroll in the open -label extension trial.
bRandomization will be stratified by site and the status of background ADT therapy (with or without background ADT).
cExtension of screening may be requested and discussed w ith the medical monitor prior to the expiration of the screening period.
dSubjects who complete all trial visits through Week 12 with no major protocol deviations may be offered entry into an open -label extensi on trial.
Figure 1.2
-1 Trial Design Schematic

Protocol 331/201/00242
17
Confidential -Proprietary Information Original Approval: 09 Jul 20191.3 Schedule of Assessments
Table 1.3-1 Schedule of Assessments
AssessmentVisit
Screeninga
(Day -21to 
Day -1)Double -Blind Treatment Period
Post-
treatm ent 
Follow -up
(21 ± 2 
days)d12weeks
Day 0 Week 1bWeek 2 Week 4 Week 6 Week 8 Week 10End of 
treatm ent 
(Week 12) 
or ETc
± 2days
ENTRANCE and HISTORY
Informed consent X
Inclusion and exclusion criteria X X
Confirmation of eligibilityXe
Dem ography X
Medical history X
Psychiatric history, including 
BPD historyX
Confirm use/no use of ADTs X
SCID -5-PDfX
Diagnostic for co ncurrent 
excluded diseases ( MINI for 
Psychotic Disorders )X
Prior medication washoutgX
HIV, HBsAg, and anti -HCV X
EFFICACY
ZAN -BPD X X X X X X X X X
CGI-S X X X X X X X X
CGI-I X X X X X X X
PGI-S X X X X X X X X
PGI-C X X X X X X X
X X X X X X X X

Protocol 331 -201-00242
18
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul2020Table 1.3-1 Schedule of Assessments
AssessmentVisit
Screeninga
(Day -21to 
Day -1)Double -Blind Treatment Period
Post-
treatm ent 
Follow -up
(21 ± 2 
days)d12weeks
Day 0 Week 1bWeek 2 Week 4 Week 6 Week 8 Week 10End of 
treatm ent 
(Week 12) 
or ETc
± 2days
X X
X X X X X X
SAFETY
Physical examinationhX X
Vital signsiX X X X X X X X X
Clinical laboratory tests 
(hematology, serum chemistry, 
and urinalysis)XjX X
Prolactin (blinded) X X
TSH with reflex to free T 4if 
abnormalX
HbA1c X X
ECGkX X
Urine pregnancy test (FOCBP 
only)l X X X X X
Urine drug screen and blood 
alcohol testm X X X
C-SSRSnX X X X X X X X X
Extrapyramidal symptoms scales 
(SAS, AIMS, and BARS)X X X
Adverse eventsoX X X X X X X X X X
Concomitant therapypX X X X X X X X X X

Protocol 331-201-00242
19
Confidential - Proprietary Information Amendment 1 Approval: 07 Jul 2020Table 1.3-1 Schedule of Assessments
AssessmentVisit
Screeninga
(Day -21 to 
Day -1)Double-Blind Treatment Period
Post-
treatment 
Follow-up
(21 ± 2 
days)d12 weeks
Day 0 Week 1bWeek 2 Week 4 Week 6 Week 8 Week 10End of 
treatment 
(Week 12) 
or ETc
± 2 days
PHARMACOKINETIC AND PHARMACOGENOMIC SAMPLING
Pharmacokinetic samplingqXX
 X
X
OTHER PROCEDURES
IMP dispensingsXtXXXX X X
IMP accountability X X X X X X X
Schedule optional phone 
contact/other communicationXuXuXuXuXu
anti-HCV = antibodies to hepatitis C virus; ; ET = Early Termination; ; 
FOCBP = females of childbearing potential; HBsAg = hepatitis B surface antigen; HIV = human immunodeficiency virus; IRE = immedi ately reported 
events; PGI-C = Patient’s Global Impression of Change; PGI-S = Patient’s Global Impression of Severity; ; PK = pharmacokinetic; 
T4= thyroxine.
aExtension of screening may be requested and discussed with the medical monitor prior to the expiration of the screening period. S creening visit may be split 
over two days.
bWeek designations correspond to the end of the week (eg, Week 4 visit occurs at the end of week 4 of the trial).
cIf a subject discontinues early, every effort should be made to complete the “Week 12/End of treatment/ET” evaluations as soon a s possible and, whenever 
possible, prior to starting any new medication or treatment.
dTelephone contact or clinic visit (investigator’s discretion) for evaluation of safety (AEs) for all subjects who do not enroll i n the open-label extension trial.
eAn assessment of all inclusion and exclusion criteria will be made to determine the subject’s eligibility for the trial . Subje cts cannot be enrolled 
until site personnel have received the final  notification from the Medical Monitor or Clinical Scientist.CCI
CCI
CCI
Protocol 331 -201-00242
20
Confidential -Proprietary Informatio n Amendment 1 Approval: 0
7Jul2020fThe BPD and antisocial personality disorder modules must be conducted as part of screening in order to meet inclusion /exclusion criteria; however, per 
investigator discretion other PD modules may be administered at baseline in order to decrease the length of the screening visit. The investigator is 
responsible for determining that BPD is the primary personality disorder diagnosis at screening .
gWashout of prohibited medications begins after completion of the consent process and must comply with the required washo ut periods (see Section 6.5)
.
hTo include measurement of height (at screening only) and waist circumference.
iVital sign measurements include body weight, body temperature, systolic and diastolic blood pressure, and heart rate. Blood pressure and heart rate will be 
measured in the following order: supine and standing after the subject has been in each position for at least 3 minutes. Vital signs scheduled for the same 
visit as blood samples are to be completed before blood is drawn.
jBlood samples for clinical laboratory tests should be draw n after a minimum 8 -hour fast at screening, if possible. If the Screening Visit labora tory samples 
were not obtained under fasting conditions, clinical laboratory tests (hematology, serum chemistry [including blinded prolact in], HbA 1c, TSH with reflex 
to 
free T4if the result for TSH is abnormal, and urinalysis) need to be obtained under fasting conditions at the Day 0 Visit .Vital sign and ECG assessments 
should be completed before any blood samples are collected.
kStandard ECGs will be performed after the subje ct has been supine and at rest for 5 minutes prior to the ECG. Any screening ECG with abnormal result(s) 
considered to be clinically significant should be repeated to ensure reproducibility of the abnormality before excluding a subject. For ECG, perform 3 
consecutive recordings. If 2 of the 3 remain exclusionary then the subject must be excluded . 
lAll positive urine pregnancy test results must be confirmed by a serum test. Pregnancy tests can be performed at any point du ring the trial if pregnancy is 
suspected.
mA urine drug screen and a blood alcohol test are required at the designated times, but either or both can be conducted at any time during the trial at the 
discretion of the investigator. See the exclusion criteria for exclusions based on urine dru g screen and blood alcohol tests at screening.
nThe “Baseline/Screening” C -SSRS form will be completed for all subjects at screening to determine eligibility and the “Since Last Visit” C -SSRS form will 
becompleted at the Day 0 Visit to ensure that the sub ject continues to qualify for the trial. The “Since Last Visit” C -SSRS form will also be completed at 
all visits after the Day 0 Visit.
oAdverse events will be recorded starting after the subject completes the consent process and through the last scheduled trial visit (IREs will be collected 
through the last trial contact) .
pAll prescription and non -prescription therapy (pharmacological or other therapy) taken during the trial will be recorded .Details of prohibited therapies are 
provided in Section 6.5.1 .
qAPK sample will be collected at the same time of collection of clinical laboratory assessments, where applicable. Time of last 3 doses will be recorded at the 
time of PK sampling.
 
.

Protocol 331 -201-00242
22
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20202 Introduction
Borderline personality  disorder (BPD) is a mental disorder consisting of a pervasive 
pattern of instability  in regulation of emotions, impul se control, interpersonal 
relationships, and self image.1,2Patients with BPD are prone to self -harm (including 
suicid al behavior/ideation ), other dangerous behaviors, substance ab use, depression and 
eating disorders.3The prevalence of BPD has been reported to be as high as 5.9% in the 
general population4but represents 15% to 29% of patients in psy chiatri c clinics and 
hospitals.5,6Because the personality of children and adolescents is developing, the 
features of BPD do not become recognizable until late adolescence or earl y adul thood.7,8
There is a high comorbidity  of BPD with other psy chiatric disorders (approximately  
85%), including anxiety disorders , mood disorders , impulse -control disorders , and 
substance -usedisorders.9
Brexpiprazole (REXULTI®) is an 
atypical antipsychotic that is a serotonin -dopamine 
activity  modulator and is indicated in the United States (US) as monotherapy  for the 
treatment of schizophrenia in adult patients (2 -4 mg/day ) and as an adjunctive therapy  to 
antidepressants for the treatment of major depressive disorder (MDD) (2 - 3mg/day ).10
While the precise mechanism of action of brexpipra zole in treating psy chiatric conditions 
is unknown, the pharmacology  of brexpiprazole is believed to be mediated by  a 
combination of high -binding affinity  and functional activities at multiple monoaminergic 
receptors. It has modulatory  activity  at the serotonin and dopamine sy stems that 
combines partial agonist activity  at serotonergic 5 -HT1Aand at dopaminergic D 2
receptors with antagonist activity  at serotonergic 5 -HT2Areceptors, with similar high 
affinities at all of these receptors (inhibition constant [Ki]: 0.1 -
0.5nM). Brexpiprazole 
also shows antagonist activity  at noradrenergic α 1B/2C receptors with affinity in the same 
sub-nanomolar K irange (K i: 0.2 - 0.6 nM). The 5- HT1A/D2receptor partial agonist 
activity  in combination with 5 -HT2Aand α 1B/2C receptors antagonism of brexpiprazole 
may correlate with antipsy chotic and antidepressant efficacy , reduced impulsive 
behavior, and cognitive improvement.10
Please refer to the Brexpiprazole Inv estigator’s Brochure for more detailed information.
2.1 Trial Rationale
There are currently  no pharmacological treatments approved for BPD. The first -line of 
treatment is psy chotherapy , including dialectic behavior therap y to manage emotions, 
Protocol 331 -201-00242
23
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020help with tolerating distress, and managing relationships.7Pharmacotherapy is used to 
treat targeted s ymptoms that fall within the following categories: 1) affective 
dysregulation, mood lability , and anger, 2) impulsive and self -harming behavior, and 3)
cognitive perceptual s ymptoms. Based on off -label prescribing practices and on clinical 
trial data , there is evidence that at ypical antipsychotics may  be efficacious at treating 
patients with BPD, especially  symptoms of mood, self -harm, impulsivity , and a ggression. 
Reductions in overall BPD sy mptomatology  have been demonstrated in clinical trials of 
quetiapine11olanzapine12,13,14clozapine15,16and aripiprazole.17,18
This receptor activi ty profile may  allow for effective pharmacotherapy  for the treatment 
of BPD. More specifically, the serotonergic and dopaminergic stabilization and 
modulation provided by  brexpiprazole may  directly  address the pathway s implicated in 
the BPD features of imp ulse aggression (serotonergic) and emotional d ysregulation and 
impulsivity  (dopaminergic).
The proposed 12
-week, double -blind, placebo -controlled trial will be conducted to 
evaluate the efficacy  and safet y of brexpiprazole for the treatment of subjects dia gnosed 
with BPD.
2.2 Background
A complete description of the available efficacy  and safet y pharmacology data from 
nonclinical studies, including pharmacokinetic (PK) and toxicology  studies in different 
animal species can be found in the current IB .10
Currently , brexpiprazole is approved in multiple countries for use in adult patients for the 
treatment of schizophrenia, and for the use as an adjunctive therap y to antidepre ssants for 
the treatment of MDD . Additionally , the current clinical development program is 
designed to show safet y and efficacy  of brexpiprazole for the treatment of the following 
indications: treatment of adult post- traumatic stress disorder (PTSD), bipolar mania, 
adolescent schizophrenia, and the treatm ent of agitation in Alzheimer’s disease ( AAD).10
As of 17 Apr 2018, the brexpiprazole clinical development program consisted of a total 
of 74 clinical trials conducted in North America, Latin America, Europe, and As ia 
(66completed and 8 ongoing). This includes 67 trials conducted under US 
Investigational New Drug (IND) Applications (59 completed and 8 ongoing) for 
schizophrenia, adjunctive treatment of MDD, adjunctive treatment of 
attention -deficit/hy peractivity  disorder (ADHD), AAD, PTSD, or bipolar; and 7 non -US 
IND trials (7 completed and 0 ongoing) in either South Korea or Japan conducted in 
healthy  subjects and subjects with schizophrenia.10
Protocol 331 -201-00242
24
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Please refer to the IB for a detailed summary  of available clinical data.10
2.3 Know n and Potential Risks and Benefits
As of 17 Apr2018, a total of 9153 unique subjects were exposed to single or multiple 
doses of brexpiprazole (either alone or wit h another marketed drug) in US IND trials. 
This total includes 877 subjects in the collective phase 1 clinical pharmacology  trials
(593 health y subjects or subjects in special populations and 284 subjects diagnosed with 
either schizophrenia or schizoaffective disorder [N = 236], MDD [N =36], or ADHD 
[N= 12]) and 8276 subjects diagnosed with either schizophrenia or schizoaffective 
disorder (N = 2404), MDD (N =5265), AAD (N = 429), ADHD (N =155), or PTSD 
(N=23) in the collective phase 2 and phase 3/3b t rials. 
Overall, the total number of subject years of exposure (SYE) in the completed phase 1 
clinical pharmacology  trials (N = 877) and all phase 2 and phase 3/3b trials combined 
(N=8276) was 28.5 and 3590.3 SYEs, respectively . Exposure to brexpiprazole in the 
completed phase 2 and phase 3/3b US IND trials is summarized by  duration of exposure 
and indication in the current IB.10The majorit y of subjects within each of the 5 
indications have received at least 6 week s of brexpiprazole, including 3139 subjects with 
at least 26 weeks of exposure and 1612 subjects with at least 52 weeks of exposure.
Completed phase 2 and phase 3 clinical trials have evaluated multiple oral doses up to 
6mg/day  in subjects with schizophre nia, up to 3 mg/day  when coadministered with 
marketed antidepressant therap y in subjects with MDD, up to 3 mg/day  in subjects with 
PTSD, up to 2 mg/day  when coadministered with marketed stimulant therapy  in subjects 
with ADHD, and up to 2 mg/day  in subject s with AAD. Dose selection for the ongoing 
multiple -dose trials was derived from the collective safet y, efficacy
, and receptor 
occupancy  data from completed phase 1, phase 1b, phase 2, and phase 3 trials of 
brexpiprazole.
Overall, 9062 subjects received br expiprazole either alone or coadministered with 
another marketed medication from the 59 completed brexpiprazole trials conducted under 
US INDs. Overall, 6403/9062 subjects (70.7%) reported at least 1 treatment- emergent 
adverse event ( TEAE ) compared with 14 98/2781 subjects (53.9%) who received placebo 
either alone or coadministered with another marketed medication. The most frequentl y 
reported TEAEs (incidence ≥ 5% of the total brexpiprazole group and more than total 
placebo) in all subjects who received bre xpiprazole were increased weight (12.1%), 
headache (9.1%), insomnia (7.8%), akathisia (7.2%), somnolence (6.2%), and dizziness 
(5.3%). In the total placebo group, headache (8.2%) was the most frequently  reported 
TEAE (incidence ≥ 5% of subjects).
Protocol 331 -201-00242
26
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Secondary : To evaluate the safet y and 
tolerability  of brexpiprazole for the 
treatment of subjects with a diagnosis of 
BPDFrequency  and severity  of AEs
Changes in ECGs , vital signs, 
clinical laboratory  tests including 
blinded prolactin, changes in body  
weight, and phy sical examinations
EPS:SAS, the AIMS, and the 
BARS
Suicidal ideation and behavior will 
be assessed using the 
C-SSRS
AE = adverse event; AIMS = Abnorm al Involuntary Movement Scale; BARS = CGI -I = Clinical Global 
Impression -Improvement of Illness ; CGI -S = Clinical Global Impression -Severity of Illness ;  
 C-SSRS = Columbia -Suicide Severity Rating 
Scale ; Barnes Akathisia Rating Scale ; ECG = electrocar diogram;  
PGI-C = Patient’s Global Impression of Change ; PGI -S = Patient’s Global 
Impression of Severity ; SAS = Simpson Angus Scale ;  
 ZAN -BPD = Zanarini Rating Scale for Borderline Personality
Disorder .
Section 9.4 describes the statistical analy sis of the e ndpoints.
4 Trial Design
4.1 Type/Design of Trial
This will be a 12-week, multicenter, randomized, double- blind, placebo -controlled trial of 
brexpiprazole in subjects diagnosed with BPD according to the Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition (DSM -5) and confirmed b y a valid diagnostic 
instrument ( Structured Clinical I nterview for DSM -5 Personality  Disorders 
[SCI D
-5-PD]). 
The trial will be organized as follows:
Screening Period: The screening period will begin after written informed consent has 
been obtained and will take place between Day  −21and Day  −1 prior to enrollment. 
Eligible subjects are required to meet all inclusion criteria at both screening and Day 0, 
including a tot al score of ≥12 on the 
Zanarini Rating Scale for Borderline Personality  
Disorder (ZAN -BPD ).In addition, a score of ≥ 2 in at least 2 of the following 
4ZAN -BPD subscale items will be required at screening and Day 0: 1) “inappropriate, 
intense anger or difficulty  controlling anger” (hereafter referred to as inappropriate 
anger), 2) “transient stress
-related paranoid ideation or severe dissociative sy mptoms” 
(paranoid ideation), 3) “affective instability  due to a marked reactivity  of mood” 
(affective inst ability ), and 4) “impulsivity  in at least other two areas that are potentially  
self-damaging” (impulsivity ).Following screening, eligible subjects will enter the trial 

Protocol 331 -201-00242
27
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020andbe randoml y assigned to brexpiprazole 2 to3mg/day  or placebo in a 1:1 fashion. 
Randomization will be stratified b y site and the sta tus of background antidepressant
therap y (ADT) use (with background ADT or without background ADT).
Treatment Period: Subjects will receive their assign ed treatment during a 12-week, 
double -blind treatment period . The primary  endpoint and the key  secondary endpoint will 
be the change from baseline 
in the ZAN- BPD total score and Clinical Global I mpression 
Scale - Severity  of Illness (CGI -S) score, respectively . Visits will occur at Day 0and at 
the 
endof Weeks 1, 2, 4, 6, 8, 10, and 1 2, with phone contact to check on subject status 
on the weeks the subject does not visit the clinic.
Safety Follow -
up: Subjects who do not continue treatment in the open -label extension
trial will be followed up for safety  reasons via telephone contact or in clinic visit 21 (±2) 
days after the last dose of investigational medicinal product (IMP). This contact also 
applies to subjects who are withdrawn prematurely  from the trial.
See Figure 
1.2-1 for a schematic of the trial.
4.2 Scientific Rationale for Trial Design
Given its clinical efficacy in treating both schizophrenia and MDD as well as its 
multimodal mechanism of action, b rexpiprazole may  offer added benefit to patients 
suffering from BPD. Like other ps ychological disorders, BPD has been linked to 
aberrations in monoaminergic neurotransmission. While dy sfunctions related to 
dopamine and serotonin have been historicall y cite d, recent evidence has also implicated 
noradrenergic d ysfunction in BPD as well.19,20,21,22Since brexpiprazole possesses a 
multi- modal mechanism of drug action, pharmacologicall y, it may  improve defects in 
monoamine circuitry  that have gone awry  in this psy chiatric disorder. Notably , 
brexpiprazole is a partial agonist at dopamine D 2/D3and serotonin 5 -HT1Areceptors. It is 
also an antagonist at serotonin 5- HT2Aand adrenergic α 1Band α 2Creceptors. I ts 
pharmacological effects at each receptor subt ype may be beneficial in treating the diverse 
symptomology  present in patients diagnosed wi th BPD. For example, as a partial 
dopamine D 2/D3receptor agonist, brexpiprazole may quell the h yperresponsiveness in 
the dopaminergic circuitry  purported to exist in patients with BPD.23By dampening 
dopaminergic t one in overactivated circuits, brexpiprazole may  improve impulsivity  and 
cognitive and emotional processing. Conversel y, brexpiprazole may  also improve 
dopaminergic tone i
n those circuits that are under stimulated to improve mood. L ikewise, 
brexpiprazole ma y normalize aberrations that are believed to exist in a heightened 
adrenergic s ystem.23Since the noradrenergic s ystem is one of the effectors of the stress 
Protocol 331 -201-00242
28
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020response and likel y activated with childhood trauma, it is postulated that noradrenergic 
genetic variants may  confer BPD risk.22Furthermore, 5 -HT2Areceptors are expressed on 
locus coeruleus noradrenergic neurons.24In this regard, brexpiprazole may  improve BPD 
symptomology  like affective dy sregulation, anxiety  and impulsive -aggression by  
modulating noradrenergic drive.25Impulsive -aggressive behavior is a core feature of 
BPD that may  also result from hyperactivation of the amy gdala. The am ygdala is part of 
the limbic sy stem that controls negative emotions. In BPD, loss of inhibitory  regulation 
of the am ygdala may occur from alterations in the 5 -HT1Areceptor gene, HTR1A, in 
some individ uals.21In these individuals, serotonergic function is reduced. Low levels of 
serotonin may  lead to anger, suicidality , impulsivity , and aggressive behavior. Given its 
agonistic effects on both pre -and post -synaptic 5-HT1Areceptors, brexpiprazole may  
help negativel y modulate these behaviors, respectively, b y normalizing serotonin 
neurotransmission. 
This phase 2, 2
-arm trial is intended to provide preliminary  evidence that treatment of 
subjects with BPD with brexpipr azole is superior to placebo .  
4.3 Dosing Rationale
The dosing paradigm of brexpiprazole t o be used in Trial 331 -201-00242 has been 
determined based on the dosing ranges investigated in other related ps ychiatric 
indications (bipolar I disorder, MDD, PTSD, and schizophrenia).10
In other ps ychiatric indications, brexpiprazole has been shown to be safe and well 
tolerated within the proposed dose range to be investigated in this trial (ie, 2 to
3mg/day ). In addition, the effective dose range for approved indications (MDD and 
schizophrenia) is 2 to 4 mg/day ; the 1 mg/day  dose has not been shown to be effective. 
4.4 End of Trial Definition
The end of trial date is defined as the last date of contact or the date of final contact 
attempt from the post
-treatment safet y follow -up eSource page for the last subject 
completing or withdrawing from the trial.
4.5 Definition of Completed Subjects
The treatment period is defined as the time period during which subj ects are evaluated for 
primary  and/or secondary  objectives of the trial irrespective of whether or not the subject 
actuall y consumed all doses of the IMP. Subjects who are evaluated at the last scheduled 
visit during the treatment period will be defined as trial completers. For purposes of this 
trial, subjects who complete Week 12 will be defined as trial completers.
Protocol 331-201-00242
29
Confidential - Proprietary Information Amendment 1 Approval: 07 Jul 20205 Trial Population
It is planned that approximately 240 subjects will be enrolled at approximately 65 trial 
sites in the US and Europe.  
 
 
 
The sponsor reserves the right to utilize external quality oversight methods to ensure the 
validity of diagnosis, severity of illness, and other factors determining appropriateness of 
subject selection.
Decisions regarding inclusion of subjects at time of enrollment and assessment of subject 
safety throughout the trial primarily remain at the discretion of the investigator; however, the medical monitor may recommend exclusion or discontinuation of a subject based on 
individual subject data.
5.1 Subject Selection and Numbering
All subjects will be given a unique subject identifier (ID; site number [3 digits] + subject 
number [‘S’ + 5 digits] upon providing consent [or assent if applicable]). Site number 
will be designated by the sponsor. The subject number will be given sequentially from 
S00001 as the serial numbers in the trial sites.
Demographic information (collection date, date of birth, sex, childbearing potential, race, 
ethnicity) and medical history will be recorded in eSource at screening visit.
Eligible subjects who are enrolled in the trial will be assigned a unique subject 
randomization number for treatment sequence assignment. Results of the eligibility assessment, date of randomization (or date of treatment assignment) and subject ID (or treatment group) will be recorded in eSource.
5.2 Eligibility Criteria
5.2.1 Inclusion Criteria
Subjects are required to meet the following inclusion criteria at the time points described 
in the schedule of assessments ( Table 1.3-1 ).
1) Male or female subjects, ages 18 to 65 years, inclusive, at the time of informed 
consent.
2) Subjects who are able to complete the consent process and/or consent obtained from 
a legally acceptable representative (as required by Institutional Review Board [IRB]/Independent Ethics Committee [IEC]) prior to the initiation of any protocol-required procedures.CCI
Protocol 331 -201-00242
30
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20203)Ability , in the opinion of the principal investigator, to understand the nature of the 
trial and follow protocol requirements, including the prescribed dosage regimens, 
tablet ingestion, and discontinuation of prohibited medication, and to read and 
understand the written word in order to be reliably rated on assessment scales.
4)Subjects with a primary  DSM -5 diagnosis of BPDconfirmed b y theSCID -5-PDat 
screening .
5)At screenin g and 
Day 0, subjects must have a total score of ≥ 12 on the ZAN -BPD
scale .In addition, a score of ≥
2in at least 2 of the following 4 ZAN -BPD subscale 
items will be required at screening and Day  0: 1) inappropriate anger, 2) paranoid 
ideation , 3) affect ive instability , and 4) impulsivity .
6)Subjects who, in the investigator’s judgment, require treatm ent with a medication 
for BPD .
7)Subjects willing to discontinue all prohibited medications to meet protocol -required 
washouts prior to and during the trial peri
od.
5.2.2 Exclusion Criteria
Subjects will be excluded if they  meet any  of the following exclusion criteria at the time 
points described in the schedule of assessments ( Table 1.3-1).
Sex and Reproductive Status
1)Sexually  active males 
or females of childbearing potential ( FOCBP )who do not 
agree to practice 2 different methods of birth control or remain abstinent during the 
trial and for 30 day s after the last dose of IMP. If employ ing birth control, 2 of the 
following precautions must be used: vasectom y, tubal ligation, vaginal diaphragm, 
intrauterine device, birth control pill, birth control implant, birth control depot 
injection, condom with spermicide, or sponge with spermicide.
Consensual sexual activity  that cannot biologically result in pregnancy  may  not be 
subject to requi red birth control methods, following discussion with the medical 
monitor .
Male subjects must also agree not to donate sperm from trial screening through 30 
days after the last dose of I MP.
2)Women who are breastfeeding and/or who have a positive pregnancy  test result 
prior to receiving IMP.
Target Disease
3)Subjects with a concurrent DSM -5 diagnosis of sch izophrenia or schizoaffective 
disorder are excluded. Subjects with a historical diagnosis of schizophrenia or 
schizoaffective disorder may  be permitted if the investigator determines and 
documents that this prior diagnosis was not appropriate based on current and 
historical presentation. Also, subjects with a concurrent diagnosis of bipolar I 
disorder, 
bipolar II disorder, delirium, dementia, amnesia , eating di sorder, antisocial 
personality  disorder ,or other cognitive disorders are excluded. Subjects with MDD , 
PTSD , ADHD, panic disorder, or generalized anxiety  disorder can be included 
under the following conditions: sy mptoms have been stable for at least 6 0 day s prior 
Protocol 331 -201-00242
31
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020to screening, these disorders are not the primary focus of treatment, and changes in 
any treatment for these disorders (permitted medication and/or psy chotherapy ) 
would not likely  be required for the duration of the trial . All other concurrent
psychiatric or neurological diagnoses must be discussed with the medical monitor.
4)Subjects who are currently in ps ychotherap y specifically used to target BPD 
symptoms at the time of screening (eg , dialectical behavior therap y, 
mentalization -based therapy ) or who have participated in BPD -targeted 
psychotherap y within 60 days of screening are excluded. I ndividual or group 
supportive talk therap y, or other non -pharmacological interventions, may  be 
permitted provided the treatment has not been in itiate d or a changed within 60 days 
prior to the screening visit, and if is not anticipated that that the subject will require 
changes in this treatment during the trial.
5) Subjects who have had electroconvulsive treatment or transcranial magnetic 
stimulatio n within 90 days prior to the screening visit .
Medical History and Concurrent Diseases
6)Subjects who have a current diagnosis of substance or alcohol use disorder 
(excluding nicotine) (DSM
-5 criteria) within 90 day s prior to the screening visit.
7)Subjects who fulfill the following criteria related to suicide and/or suicidal ideation 
are excluded:
Subjects who have a significant risk of committing violent acts, serious self- harm, 
or suicide based on history or routine ps ychiatric status examination, or those w ho 
are homicidal or considered to be a high risk to others, or subjects with a response 
of “y es” on the C -SSRS Suicidal I deation Item 5 (Active Suicidal Ideation with 
Specific Plan and Intent) within the 90 day s prior to screening or at 
Day 0, OR
Subjects 
with a response of “y es” on the C -SSRS Suicidal Behavior Items Actual 
Attempt, I nterrupted Attempt, or Aborted Attempt within the 90 day s prior to 
screening or at Day  0, OR
Subjects w ho have had 3 suicide attempts within 2 y
ears prior to screening , OR
Subjects who have had 3 or more hospitalizations due to suicidal behavior wi thin 
12 months prior to screening. 
Note that subjects who have engaged in non -suicidal self -injurious behavior within 
the 90 day s prior to screening or at Day 0 are eligible, unless t he behavior is better 
described as an actual attempt, interrupted attempt, or aborted attempt according to 
C
-SSRS definition and/or investigator judgment and therefore exclusionary.
Subjects with a response of “y es” on the C -SSRS Suicidal I deation Item 4 ( Active 
Suicidal I deation with Some I ntent to Act, with outSpecific Plan and Intent) within 
the 90 day s prior to screening or at Day 0 may  be included following discussion 
with the medical monitor.
8)Subjects with hy pothy roidism or hy perthy roidism (unless condition has been 
stabilized with medications for at least 90 days prior to screening) or an abnormal 
result for free T 4 at screening.
Protocol 331 -201-00242
32
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20209)Subjects who currently  have clinicall y significant neurological, hepatic, renal, 
metabolic, hematological, immunological, c ardiovascular, pulmonary , or 
gastrointestinal disorders such as the following:
Any history  of m yocardial infarction or congestive heart failure (whether 
controlled or uncontrolled)
Human immunodeficiency virus (HIV) seropositive status or acqu ired 
immunode ficiency  syndrome
Chronic hepatitis B or C (defined as positive serology  and aspartate 
aminotransferase [AST] or alanine aminotransferase [AL T] elevated to > 2 × 
upper limit of normal [ULN])
Medical conditions that are minor or well- controlled may  be cons idered acceptable 
if the condition does not expose the subject to an undue risk of a significant AE or 
interfere with assessments of safety or efficacy during the course of the trial. The 
medical monitor should be contacted in an y instance where the invest igator is 
uncertain regarding the stability  of a subject’s medical condition(s) and the potential 
impact of the condition(s) on trial participation. Subjects who are severel y obese, as 
confirmed b y a correspondingl y high body  mass index ( BMI ), need to be r eviewed 
and discussed with the medical monitor.
10)Subjects with diabetes mellitus (both insulin- dependent and non -insulin -dependent) 
may be eligible for the trial if their condition is stable and well -controlled as 
determined b y satisfying ALL of the following criteria:
a)Glycosylated hemoglobin ( HbA1c )< 8.0%, AND
b)Screening glucose must be 125mg/dL (fasting ) or < 200mg/dL 
(non-fasting). If the non -fasting screening glucose is 200mg/dL , subjects 
must be retested in a fasted state and the retest va lue must be 125mg/dL, 
AND
c)Subject has not had an y hospitalizations within the 12 months prior to 
screening due to diabetes or complications related to diabetes .
Subjects with non- insulin -dependent diabetes mellitus (ie, any  subjects not using 
insulin) must also satisfy  the below criterion :
a)Subject has been maintained on a stable regimen of antidiabetic medication(s) 
for at least 28 day s prior to scre ening or diabetes has been well -controlled by  
diet for at least 28 day s prior to screening .
Subjects with newly  diagnosed diabetes during screening are excluded.
11)Subjects wi th uncontrolled hy pertension, sy mptomatic hy potension, or orthostatic 
hypotension (see Section 8.7.3).
NOTE: Blood pressure measurements may  be repeated once to ensure 
reproducibility  of the exclusionary  result(s) before excluding a subject based on the 
criteria noted above.
12)Subjects with epilepsy  or a history  of seizures, except for a single seizure episode; 
for instance childhood febrile, post traumatic, or alcohol withdrawal seizure.
Physical and Laboratory Results
Protocol 331 -201-00242
33
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202013)Subjects with abnormal laboratory  tests results, vital signs results, or ECG findings, 
unless, based on the investigator’s judgment, the findings are not medicall y 
significant and would not impact the safet y of the subject or the interpretation of the 
trial results. The medical monitor should be contacted to discuss individual cases, as 
needed. 
In addition, subjects with the following laboratory  test and ECG results at screening 
must be excluded from the trial:
Platelets ≤ 75000/mm3
Hemoglobin 
≤ 9 g/dL
Neutrophils, absolute ≤ 1000/mm3
AST > 2 × ULN
ALT > 2 × ULN
Creatine phosphokinase ( CPK )> 3 × ULN, unless di scussed with and 
approved b y the medical monitor
Creatinine ≥ 2 mg/dL
QTcF ≥ 450 msec in men and ≥ 470 msec in women, unless due to ventricular 
pacing.
Tests with exclusionary  results should be repeated to ensure reproducibility of the 
abnormality  before excluding a subject based on the criteria noted above. For 
ECG, perform 3 consecutive recordings. If 2 of the 3 remain exclusionary  then the 
subject must be excluded.
14) Subjects with a positive drug screen for cocaine or other illicit drugs are excluded 
and may not be retested or rescreened. Subjects with a positive urine drug screen 
resulting from use of cannabis , or prescription or over-the counter medications ,or 
products that ,in the investigator’s documented opinion ,do not signal a clinical 
condition that would impact the safety of the subject or interpretation of the trial 
results may  continue evaluation for the trial following consultation and approval by  
the medical monitor. Subjects with positive results for alco hol use will require 
consultation and approval by  the medical monitor in order to verify  use does not 
indicate a substance -use disorder.
Disallowed and Concomitant Medication
15)Recent treatment with a prohibited therap y(atable of prohibited therapies along
with required wash- out periods is provided in Section 6.5.1)
16)Subjects who would be likely  to require prohibited concomitant therapy  during the 
trial (
see Section 6.5). 
17)Subjects who received brexpiprazole in any  prior clinical trial or subjects who have 
taken or are currentl y taking commerciall y available brexpiprazole (Rexulti®).
Allergies and Adverse Drug Reactions
18)Subjects with a history  of neuroleptic malignant s yndrome, serotonin s yndrome, or 
clinically
 significant tardive dy skinesia.
Protocol 331 -201-00242
34
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202019)Subjects with a history  of true allergic response (ie, not intolerance) to more than 1 
class of medications.
20)Subjects who are known to be allergic or h ypersensitive to brexpiprazole or other 
quinolinones.
Other
21)Prisoners or subjects who are compulsoril y detained (involuntarily incarcerated) for 
treatment of either a ps ychiatric or ph ysical (eg, infectious disease) illness must not 
be enrolled into this trial.
22)Subjects who are currently either inpatient or partially  hospitalized should not 
participate in the trial.
23) Subjects who participated in a clinical trial within 90 days prior to screening or who 
participated in more than 2 clinical trials within a year prior to screening .
24)Any subject who, in the opinion of the sponsor, investigator, or medical monitor, 
should not participate in the trial.
A definition of childbearing potential can be found in Section
10.3.
Subjects must agree to restrictions to medications described inSection
6.5.No 
restrictions to activity , food, caffeine, alcohol or tobacco or an y other lifestyle 
considerations are needed during this trial.
5.3 Lifesty le Considerations
Not applicable.
5.3.1 Meals and Dietary  Restrictions
Not applicable.
5.3.2 Caffeine, A lcohol, and Tobacco
Not applicable.
5.3.3 Activity
Not applicable.
5.4 Screen Failures
A screen failure is a subject from whom informed consent is obtained and is documented 
in writing (ie, subject signs an informed co nsent form [I CF]), but who is not enrolled or 
assigned trial treatment.
Subjects who sign an ICF but who are not started on t reatment are permitted to be 
re-screened. In the event that the subject is re -screened for trial participation, and the 
Protocol 331 -201-00242
37
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20206.2.4 Returns and Destruction
The IMP will be destro yed by the clinical trial site. The IMP may  only  be destroy ed by 
the trial site(s), if approved by  the sponsor and if the IMP destruction meets all local 
regulations. Accountability  of the IMP must be completed and verified b y the assigned 
trial monitor prior to destruction. The trial site(s) may  utilize qualified third -party 
vendors for IMP destruction.
6.2.5 Reporting of Product Quality  Complaints
A Product Quality  Complaint (PQC) is any  written, electronic, or verba l communication 
by a healthcare professional, consumer, subject, medical representative, Competent 
Authority , regulatory  agency , partner, affiliate or other third part y that alleges 
deficiencies or dissatisfaction related to identity , quality , labeling, pa ckaging, reliability , 
safet y, durabilit y, tampering, counterfeiting, theft, effectiveness, or performance of a drug 
product or medical device after it is released for distribution. Examples include, but are 
not limited to, communications involving the foll owing:
Failure/malfunction of a product to meet an y of its specifications
Incorrect or missing labeling
Packaging issues (eg, damaged, dirty , crushed, missing product)
Blister defects (eg, missing, empt y blisters)
Bottle defects (eg, under/over- fill, no sa fety seal)
Vial defects
Product defect (eg, odor, chipped, broken, embossing illegible)
Loss or theft of product
6.2.5.1 Eliciting and Reporting Product Quality  Complaints
The investigator or designee must record all PQCs identified through an y means from the 
receipt of the IMP from the sponsor or sponsor’s designee, through and including 
reconciliation and up to destruction, including subject dosing. The investigator or 
designee must notify  the sponsor (or sponsor’s designee) b y e-mail within 24 hours of 
becoming aware of the PQC according to the procedure outlined below.
Send information required for reporting purposes (listed below) to
It should also be indicated if the complaint sample is available or not available for 
return .

Protocol 331 -201-00242
38
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Identific ation of a PQC by  the subject should be reported to the site investigator, who 
should then follow one of the reporting mechanisms above.
6.2.5.2 Information Required for Reporting Purposes
Description of compla int
Reporter identification (eg, subject, investigator, site, etc.)
Reporter contact information (eg, address, phone number, e- mail address)
ID of material (product/compound name, coding)
Clinical protocol reference (number and/or trial name)
Dosage form/strength (if known)
Pictures (if available)
Availability  for return
6.2.5.3 Return Process
Indicate during the report of the PQC if the complaint sample is available for return. If 
complaint sample is available for return, return it in the product retrieval package, which 
will be provided by  the sponsor.
It must be documented in the site accountabilit y record that a complaint sample for a 
dispensed kit has been forwarded to the sponsor for complaint investigation.
6.2.5.4 Assessment/Evaluation
Assessment and evaluation of PQCs will be handled by  the sponsor.
6.3 Measu res to Minimize/A void Bias
Procedures for breaking the blind can be found in Section 8.8.7.
During the entire tria l, treatment will be double -blind. In other words, neither the 
investigator nor the subject will have knowledge of the treatment assignment at any  given 
visit.  
Treatment assignments will be based on a computer
-generated randomization code 
provided b y the Otsuka Pharmaceutical Development & Commercialization, I nc. (OPDC) 
Biometrics Department. The randomization w ill be stratified by site and the status of 
background ADT use (with background ADT or without background ADT) . Sponsor 
personnel, including those involved in monitoring, data management, and data anal ysis, 
will not have access to the treatment code during the trial. Access to the treatment codes 
will be restricted to personnel charged with generating and maintaining randomization 
Protocol 331 -201-00242
39
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020files, packaging IMP, operating the Interactive Response Technology , and reporting 
serious adverse events (SAEs) to regulatory  agencies.
6.4 Subject Compliance
Responsible trial personnel will dispense the IMP (ie, brexpiprazole or placebo). 
Accountability  and compliance verification should be documented in the subject’s trial 
records. Subjects must be counseled on the importance of taking the IMP as directed at 
all trial visits. I f poor compliance continues (eg, multiple missed doses resulting in less 
than 80% overall com pliance at an y point in the trial), discontinuation of the subject from 
the trial should be considered. Subjects who habitually  miss visits or habitually  attend 
visits outside of the protocol- defined visit window are also noncompliant and should be 
conside red for discontinuation. The medical monitor should be contacted if the 
investigator is uncertain whether a subject’s compliance issues merits discontinuation 
from the trial.
6.5 Concomitant Medications or Therapies
The investigator will recor d all available information for medications and therapies used 
for treatment of sy mptoms of BPD and other ps ychiatric conditions prior to the trial and 
through the end of the evaluation period (defined as the time period during which 
subjects are evaluated for primary  and/ or secondary  objectives) on the eSource. 
Therapies 
used for the treatment of other conditions will be recorded from 30 day s prior to signing 
the ICFthrough the end of the evaluation period on eSource . The investigator will also 
record all medications and therapies taken b y the subject for treatment of an AE or which 
caused an AE until the end of the trial (defined as the last date of contact or date of final 
contact attempt) on eSource .
For concomitant medications, the following will be recorded in eSource : medication, 
indication, dose, frequency , route, start date and end date. For concomitant therapy , the 
following will be recorded in eSource : therapy , indication, start date and end date , and 
frequency .
6.5.1 Prohibited Medications
All subjects must agree to di scontinue all prohibited medications during the screening 
period in order to meet the protocol -specified washout periods. Table 6.5-1 provides the 
required duration of washout for selected prohibited medications. All other prohibited 
medications must be discontinued at least 24 hours before the first dose of IMP.
Extensions to the screening period in order to achieve the appropriate wash -out periods 
may be p ermitted following discussion with the medical monitor. 
Protocol 331 -201-00242
40
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Table 6.5-1 List of Medications Prohibited Before the Trial
1. Neuroleptic agents (depot or long -acting injectable) One full cycle plus 1/2 cycle
2. Monoamine oxidase inhibitor 14 days
3.Antipsychotic agents (oral)a
Oral aripiprazole
Oral cariprazine
Other oral antipsyc hotic agents (except for quetiapine
when used for insomnia )b14 days
28 days
7 days
4. Benzodiazepines (stable doses of short -acting [eg, lorazepam 
up to 2 mg/day or equivalent] and long -acting, [eg, 
clonazepam up to 1 mg/day ]may be allowed)c7 days
5.Hypnotics, including ramelteond 7 days
6. Mood stabilizers (ie, lithium ) 7 days
7. Anticonvulsants (except for gabapentin when used to treat 
anxiety or pain, after discussion with the medical monitor). 7 days
8. Antidepressant therapy

Multiple concurrent ADTs at a therapeutic dose range (for 
depressive symptoms) are not permittede
Tricyclic antidepressants and trazodone are excluded 
unless they are being used for sleep management (further 
discussion with the medical monitor is required before 
allow ing these medications)14 days
9. Ketamine , esketamine, arketamine within 90 days prior to 
screening90 days
10. Investigational agents within 90 days prior to screening 90 days
aIfa subject w as exposed to 2 or more atypical antipsychotic agents in the 12 months prior to screening 
or if the subject did not show  improvem ent on their previous atypical antipsychotic therapy, 
addition aldiscussion with the medical monitor is required .
bQuetiapine , if being used for treatment of insomnia at low doses (eg, 25 to 50 mg) ,maybe w ashed out 
24 hours prior to enrollment.
cChronic, stable (ie, regularly scheduled maintenance do se that has not changed within 6 0 days of 
screening) use of specific oral benzodiazepines is permitted for the treatment of anxiety up to a 
maximum of 2 mg/day lorazepam (or equivalent ) or1 mg/day  clonazepam .
dChronic, stable (ie, regularly scheduled maintenance dose that has not changed within 6 0 days of 
screening) use of non -benzodiazepine sleep aids is permitted for the management of sleep. 
eChronic, stable (ie, regularly scheduled maintenance do se that has not changed within 6 0 days of 
screening) t reatment with 1 ADT is permitted ; however, do ses may not exceed >60 mg/day for 
fluoxetine and > 50 m g/day for paroxetine.
Table 6.5-2 lists all medications prohibited during the trial, including exceptions, where 
appropriate.
Protocol 331 -201-00242
41
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Table 6.5-2 List of Medications Prohibited During the Trial
1. Psychotropic agents including, but not limited to, the following:
a) Antipsychotics, including depot or long -acting injectable formulations
b)Anticonvulsants (except gabapentin when used to treat anxiety or pain after further 
discussion with the medical monitor )
c)Monoamine oxidase inhibitors, tricyc lic antidepressants,atrazodone,anefazodone, fluoxetine 
(>60 mg/day) and paroxetine (> 50 mg/day)
d)Mood stabilizers (ie, lithium)
e)Benzodiazepine use is restricted to chronic, stable treatment or when used to manage 
treatment -emergent AEs such as agi tation and anxietyb
f)Hypnotics, including ramelteonc
g)Stimulants and atomoxetine 
h)Opioid analgesics, unless approval is obtained from the medical monitor. Approval for 
opioid use may be considered for a documented and clinically appropriate indicati on 
(eg,episodic pain condition, tooth extraction) if prescribed at a medically appropriate dose 
and frequency. Buprenorphine is also excluded.
i)Nutritional supplements and non -prescription herbal preparations with central nervous 
system effects (eg, St. John’s Wort, omega -3 fatty acids, kava extracts, gamma- aminobutyric 
acid supplements, etc)
j)Disulfiram
k)Prazosin -allowed if currently being taken for an appropriate indication at a stable dos e for 
at least 60 days prior to screening . Should be continued throughout trial participation
2. Investigational agents
3. Cytochrom e P450 (CYP) 2D6 inhibitors or CYP3A4 inhibitors and inducers. Selected CYP2D6 
inhibitors are: celecoxib, hydroxyzine, chloroquine, methadone, chlorpheniramine, 
moclobem ide, clemastine, clomipramine, pyrilamine, diphenhydramine, quinidine, terbinafine, 
halofantrine, tripelennamine. Selected CYP3A4 inhibitors are: amiodarone, amprenavir, 
indinavir, aprepitant, itraconazole, chloramphenicol, ketoconazole, cimetidine, nefazodone,
clarithromycin, nelfinavir, clotrimazole (if used orally), quinupristin/dalfopristin, delavirdine, 
ritonavir, diltiazem, saquinavir, erythromycin, troleandomycin, fluconazole, verapamil. Selected 
CYP3A4 inducers are: carbamazepine, oxcarbazepine, phenytoi n, dexamethasone, primidone, 
efavirenz, rifampin, nevirapine, St. John’s Wort, phenobarbitol, troglitazone. The medical 
monitor should be consulted for any questions regarding the potential for pharmacokinetic 
interactions with concomitant medications used by subjects during the trial.
4. Barbiturates
5.Beta receptor antagonistsd
6. Anticholinergic agents are prohibited within 8 hours of schedule EPS scale assessments.
aUnless they are being used for sleep management (further discussion with the medical monitor is 
required before allowing these medications)
bSee Section 6.5.2 .
cChronic, stable (ie, regularly scheduled maintenance do se that has not changed within 6 0 days of 
screening) use of non -benzodiazepine sleep aids (ie, zolpidem, zaleplon, and eszopiclone only) is 
permitted for the management of sleep but not on the same day as administration of a benzodiazepine, 
regardless of indication . Intermittent use of specific non -benzodiazepine sleep aids is permitted for 
the short term management of treatment -emergent AEs related to sleep pr oblems. For the 
non-benzodiazepine sleep aids, only 1 of the listed medications that are approved for this indication in 
the respective countries should be used and the country -specific prescribing information is to be used 
to determine the maximum allow able daily dose for the treatment of insomnia. Non-benzodiazepine 
sleep aids must not be administered w ithin 8 hours prior to scheduled efficacy and safety assessments, 
including EPS scales .
Protocol 331 -201-00242
42
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020dPropranolol is permitted for akathisia or tremor up to a maximum o f 20 mg 3 times daily (total of 
60mg/day). Propranolol mu st not be administered w ithin 8 hours prior to scheduled efficacy and 
safety assessments, including EPS scales .
6.5.2 Benzodiazepine Use During the Trial
Chronic, stable (ie, regularly  scheduled maintena nce do se that has not changed within 
60days of screening) use of specific oral benzodiazepines is permitted for the treatment 
of anxiety  up to a maximum of 2mg/day  lorazepam (or equivalent) or 1mg/day  
clonazepam in divided doses. Intermittent use of spe
cific oral benzodiazepines is 
permitted for the short term management of treatment- emergent AEs up to a maximum of 
2mg/day  lorazepam (or equivalent) or 1 mg/day clonazepam in divided doses. Short -
acting benzodiazepines are to be used whenever possible. I ncountries where no short -
acting benzodiazepines are commercially  available, use of oral clonazepam may  be 
acceptable if prior authorization is obtained from the medical monitor. The following 
guide should be used to determine approximate lorazepam equival ents: 1 mg lorazepam = 
15 mg oxazepam = 0.5 mg alprazolam = 5 mg diazepam = 0.5 mg clonazepam. If 
required for intermittent treatment of agitation, the prescribed benzodiazepine should be 
discontinued as soon as the AE for which it was initiated subsides, as per the 
investigator’s discretion to avoid any  withdrawal effects. Benzodiazepines should not be 
administered within 8 hours prior to scheduled efficacy  and safet y assessments, including 
extrapyramidal sy mptom scales. Investigators are encouraged to del ay scale 
administration until 8 hours have elapsed, if at all possible. However, if delay ing 
administration of efficacy and safet y scales is not feasible, the scales should still be 
administered and the use of benzodiazepine documented, including a notatio n of the drug 
name, dose, and time of administration on the eSource. For subjects entering the trial on 
regularl y scheduled maintenance doses of benzodiazepines, routine doses may  be taken at 
scheduled times per investigator instructions as long as drug na me, dose, date, and time 
taken are clearl y documented in eSource.
6.5.3 Permitted Medications
All medications that are not specificall y prohibited (see Section 6.5.1) are permitted but 
need to be recorded on eSource as described in Section 6.5.
6.5.4 Rescue Medications
Not applicable.
Protocol 331 -201-00242
43
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20206.6 Intervention after the End of the Trial
Subjects who complete all trial visits through the Week 12 visit and meet the inclusion 
and exclusion criteria of the open -label extension trial may be offered entry  into the
optional open -label extension trial.
7 Stopping Rules, Withdraw al Criteria, and Procedures
7.1 Entire Trial or Treatment
If the sponsor terminates or suspends the trial for any  reason, prompt notification will be 
given to investigators, IRBs/IECs, and regulatory  authorities in accordance with 
regulatory  requirements.
7.2 Individual Site
Individual trial site participation may  be discontinued by  the sponsor, the investigator, or 
the IRB/IEC if judged to be nece ssary  for medical, safety, regulatory , ethical or other 
reasons consistent with applicable laws, regulations, and Good Clinical Practice ( GCP ). 
The investigator will notify  the sponsor promptly  if the trial is terminated by  the 
investigator or the IRB/IEC at the site.
7.3 Individual Subject Discontinuation
7.3.1 Treatment Interruption
All attempts should be made to avoid treatment interruptions during the trial. If a 
subject’s IMP treatment must be interrupted for medical or surgical reasons; liver test 
abnormalities ; use of a prohibited concomitant medication; or other reasons (eg, hospital 
admission for an invasive procedure, a major medical condition, surgery ; dental work, or 
a temporary  situation that prevents subject compliance with the IMP dosing schedule), 
the subject’s IMP should be resumed as early  as the situation allows (see Section 7.3.4). 
If >4
consecutive doses of IMP are missed, a discussion should occur with the medical 
monitor to determine if the subject should be discontinued from the trial as a result of the 
treatment i nterruption.
7.3.2 Treatment Discontinuation
After treatment assignment, a subject may  stop treatment permanentl y for a variet y of 
reasons. Treatment discontinuations may  be initiated by  a subject who is not satisfied 
with treatment or may  become medicall y neces sary due to AEs, required treatment with a 
disallowed medication or therap y, or other issues, as determined b y the investigator. 
However, each investigator must comprehensivel y review the circumstances and offer the 
Protocol 331 -201-00242
44
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020subject options for continued treatment to the degree possible as described in 
Section 7.3.5.
7.3.3 Documenting Reasons for Treatment Interruption or 
Discontinuation
A subject may  temporarily  interrupt or discontinue I MP for a number of reasons , 
including those listed below:
Adverse event
Subject decides to discontinue because of anno yance or discomfort due to a 
nonserious AE which is not otherwise determined to be an undue hazard
Continuing I MP places the subject at undue risk as determined by  the investigator 
(eg, a safet y concern that is possibly , probabl y, or likely related to IMP)
SAE
Other potentially  IMP-related safety  concerns or AEs
Death
Lack of efficacy
Lost to follow -
up
Noncompliance w ith IMP
Physician decision
Pregnancy  (see Section 10.3)
Protocol deviation
Site terminated by  sponsor
Trial terminated b y sponsor
Withdrawal by  subject
If the subject temporaril y interrupts or discontinues I
MP due to an AE, the investigator, 
or other trial personnel, will make every  effort to follow the event until it has resolved or 
stabilized. Follow -up procedures in Section 7.3.1 and Section7.3.2 must be followed.
7.3.4 Withdrawal of Consent
All subjects have the right to withdraw their consent from further participation in the trial 
at an y time without prejudice. Subjects cannot withdraw c onsent for use of data already  
collected as part of the trial, but only  for future participation. The investigator can also 
discontinue a subject’s participation in the trial at any  time if medicall y necessary. Unless 
the subject provides their written withdrawal of consent or there is other written 
documentation by  the investigator confirming the subject’s verbal intent to completely  
Protocol 331 -201-00242
45
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020withdraw from the trial, subjects should be followed for all protocol -specified evaluations 
and assessments, if possible.
Complete withdrawal of consent requires a subject’s refusal of ALL of the following 
methods of follow-up:
Participation in all follow -up procedures specified in the protocol (whether in- clinic, 
by telephone, or by  an in -home visit).
Participation in a subset of protocol specified follow -up procedures (by  a frequency  
schedule and method, as agreed b y subject and staff).
Contact of the subject b y trial personnel, even if only  by telephone, to assess current 
medical condition, and obtain necessary  medical or lab oratory  reports relevant to the 
trial’s objectives.
Contact of alternative person(s) who have been designated in source records as being 
available to discuss the subject’s medical condition, even if onl y by telephone, mail, 
or e-mail (eg, famil y, spouse, p artner, legal representative, friend, neighbor, or 
physician).
Access to medical information from alternative sources (eg, hospital/clinic medical 
records, referring doctor’s notes, public records, dialy sis, transplantation or vital 
registries, social medi a sources).
Withdrawal of consent is a critical trial event and , therefore ,should be approached with 
the same degree of importance and care as is used in initially  obtaining informed consent. 
The reasons for a subject’s intended withdrawal need to be comp letely  understood, 
documented, and managed to protect the rights of the subject and the integrity  of the trial. 
A subject may  initially  express their desire to interrupt or modify ordiscontinue I MP 
administration, which is not equivalent to a complete wit hdrawal of consent for further 
participation (see Section 7.3.1 andSection 7.3.2 , respectivel y). A subject may , however, 
indicate that further trial participation is creating a burden on their work, school, or social 
schedule. Therefore, the investigator should follow the procedures outlined in 
Section 7.3.3 to determine if the subject can continue participatio n in the trial if 
modifications to his/her treatment and/or schedule of assessments can be accommodated. 
Only  subjects who withdraw their permission for all of the above methods of follow -up 
are considered to have completely  withdrawn their consent to part icipate in the trial.
7.3.5 Procedures to Encourage Continued Trial Participation
In all cases of impending I MP discontinuation or consent withdrawal, investigators will 
be instructed to meet and discuss (without undue coercion) with the subject their options 
ofcontinuing in the trial, preferabl y on therap y. The investigator should ensure 
understanding and documentation of the reasons for the subject’s desire to withdraw 
consent.
Protocol 331 -201-00242
46
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20207.4 Definition of Subjects Lost to Follow -up
Subjects who cannot be contacted on or before Week 12 during the treatment period, who 
do not have a known reason for discontinuation (eg, withdrew consent or AE), and for 
whom a survival status at the end of the trial cannot be determined will be classifi ed as 
“lost to follow -up”. Survival status can be determined from a variet y of sources, either b y 
obtaining acceptable documentation for death (ie, death certificate, medical records, 
public records, statement by  a family  member or primary  care ph ysician) or acceptable 
documentation for life (ie, direct contact with the subject, medical records, successful 
telephone contact with the subject, statement b y a family member or primary care 
physician, or public records).
The site will make 3 documented attempts to contact the subject b y telephone or other 
contact methods and in the event the site is unable to reach the subject by  telephone, the 
site will attempt to contact the subject via certified mail or an alternative similar method, 
where appropriate, before assigning a “lost to follow -up” status.
If the subject was classified as “lost to follow- up”, “Were you able to contact the 
subject?”, “Date of contact/Date of final contact attempt” and “Contact method” will be 
recorded in the source documents.
8 Trial Procedures
The assessments to be conducted during the trial and timing of assessments are 
summarized in Section 1.3.
8.1 Efficacy  Assessments
It is required that trained and experienced clinicians administer all rating scales. The 
number of raters within each trial center should be kept to a minimum. All efforts will be 
made to ensure that the same clinician administers the s
cales for a given subject. 
Notations in the subject’s trial records should substantiate the ratings. Training, 
certification, and materials for rating will be provided by  OPDC or designee. Quality  
reviews of audio recording may be performed for some assessments ,including eligibility  
review ,in order to verify the quality  of the assessment/interview and accuracy  of scoring.
8.1.1 Clinician A dministered
8.1.1.1 Zanarini Rating Scale for Borderline Personality  Disorder
The ZAN -BPD is a clinician -administered scale for the assessment of change in 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM -IV) borderline 
psychopathology .26Although the DSM -IV was updated to DSM -5, the diagnostic criteria 
Protocol 331 -201-00242
47
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020for BPD remain unchanged. The ZAN -BPD is designed to assess severit y of disease 
symptoms in patients with BPD based on clinician rating.
The questions f or the ZAN -BPD reflect a 1 -week time frame. Each of the 9 criteria for 
BPD is rated on a 5- point anchor ed rating scale of 0 to 4. These scores are clustered into 
4sector scores (akin to domains) and a total score. The 3 affective s ymptoms have a 
sector score range from 0 to 12. The 2 cognitive symptoms have a sector score range 
from 0 to 8. The 2 impulsive symptoms have a sector range from 0 to 8. The 
2interpersonal s ymptoms have a sector score range of 0 to 8. These 4 sector scores add 
up to provide the overall total score for the ZAN -BPD , which ranges from 0 to 36.
8.1.1.2 Clinical Global Impression -Severity  of Illness Scale
The severit y of illness for each subject will be rated using the CGI -S.27To perform this 
assessment, the investigator (or designee) will answer the following question: 
“Considering your tot al clinical exp erience with borderline personality disorder , how ill 
is the subject at this time?” Response choices are 0 =not assessed; 1 = normal, not at all 
ill; 2 = borderline ill; 3 = mildly  ill; 4 =moderately  ill; 5 = markedl y ill; 6 = severel y ill; 
and 7 = among the most extremely  ill subjects. 
8.1.1.3 Clinical Global Impression -Improvement Scale
Change from baseline in the subject’s condition will be assessed using the CGI -I scale.27
Theinvestigator (or designee) will answer the fo llowing question: “Rate total 
improvement whether or not in y our judgment it is due entirel y to drug treatment. 
Compared to his/her condition at Day  0, how much has the patient changed?” . All 
responses will be compared with the subject’s condition at basel ine (Day  0). Response 
choices are 0
=not assessed, 1 =very much improved, 2 =much improved, 
3 =minimally  improved, 4 =no change, 5 =minimally  worse, 6 =much worse, and 
7 =very much worse.  
 
 
 
 
 
 

Protocol 331 -201-00242
48
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20208.1.2 Patient Completed
8.1.2.1 Patient’s Global Impression -Severity
The PGI-Sis a 7- point single -item self -report scale for the patient to rate the severit y of 
symptoms of 
BPD. Subjects answer the following question: “Taking into account all of 
your symptoms, how severe is y our Borderline Personality  Disorder at this time?” Scores 
range from 1 “no s ymptoms” to 7 “very  severe ”.
8.1.2.2 Patient’s Global Impression -Change
ThePatient’s Global Impression of Change (PGI -C)is a 7
-point single- item self-report 
scale depicting a patient’s rating of overall change in thei r condition since starting trial
medication. Subjects answer the following question: “Since starting study  medication, 
how much have your symptoms of Borderline Per sonality  Disorder changed?” Scores 
range from 1 “very  much improved” to 7 “very  much worse”.
  
 
 
 
  
 
 
 
 
8.1.3 Screening A ssessme nts
8.1.3.1 Structured Clinical Interview for DSM -5 Personality  Disorders
The SCI D-5- PD33isa valid ated diagnostic instrument and will be conducted at screening
to confirm the subject’s diagnosis of BPD. Detailed instruction s for administration of this 
diagnostic interview will be provided.

Protocol 331 -201-00242
49
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20208.1.3.2 Mini International Neuropsy chiatric Interview for Psy chotic 
Disorders
The Mini I nternational Neurops ychiatric Interview (MINI) version 7.0.2 for Psy chotic 
Disorders34,35,36,37will be conducted at screening to rule out exclusionary  comorbid 
psychiatric diag noses. 
This version of the MINI is suitable for settings where specific 
psychotic disorders are a focus of interest (ie, for exclusionary  purposes). Detailed 
instructions for administration of this structured interview will be provided.
8.2 Pharmacokinetic A ssessments
ThePK sample swill be collected as described in the schedule of assessments 
(Table 1.3-1 ) . T he time of last 3 doses of IMP will be recorded at the time of PK 
sampling.
8.2.1 Pharmacokinetic Blood Samples
Blood samples will be collected in vacutainers containing sodium heparin and processed 
into plasma to determine the c oncentrations of brexpiprazole.  
 
The total volume of 
blood to be collected during the trial will be documented in the I CF.
Blood samples for PK analy sis will be collected at the time points as shown in 
Table 1.3-1 (schedule of assessments). The actual date and time of the PK sample 
collection will be recor ded in eSource .
When vital signs or ECGs are scheduled at the same nominal time as PK sample 
collections, vital signs should be measured and ECGs should be performed before PK 
samples are collected.
After processing into plasma, aliquots will be placed into appropriatel y labeled tubes and 
will be placed in a freezer set at −70° C or −20°C, unless otherwise instructed in the 
Operations/Laboratory  Manual.
All plasma samples will be shipped to the bioanaly tical laboratory  for analy sis. 
Additional information will be provided in the Operations Manual.
8.3 Pharmacody namic Assessments
Not applicable.

Protocol 331 -201-00242
51
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020 
 
 
 
 
 
 
 
 
 
8.7 Safety  Assessments
Details pertaining to the definitions, collection, reporting, and follow -up of AEs are 
described in Section 8.8.
8.7.1 Clinical Laboratory  Assessments
Clinical laboratory  samples will be collected at the time points described in the schedule 
of assessments ( Table 1.3-1) to perform the clinical laboratory  assessments described in 
Section
10.2. Vital sign and ECG assessments should be completed before any  blood 
samples are collected. Refer to Section
10.5 for criteria for identifying laboratory  values 
of potential clinical relevance.
A central laboratory  designated by  the sponsor will be used for all laboratory
 testing 
required during the trial. The central laboratory  should be used for all laboratory  testing 
whenever possible (including unscheduled and follow-up, if needed). In cases where an 
immediate result is required for a particular laboratory  test, the sample should be divided 
and sent to both a local laboratory  and the designated central laboratory . Subjects should 
be fasting for a minimum of 8 hours prior to the blood draws, if possible. If fasting blood 

Protocol 331 -201-00242
52
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020samples are not feasible at screening, nonfasting blood samples may  be obtained initially  
for determining eligibility  for the trial. A fasting blood sample is required at Day 0prior 
to dosing. If a fasting blood sample was not obtained at the Screening Visit , clinical 
laboratory  tests (hematology , serum chemistry  [including blinded prolactin], HbA 1c, TSH 
with reflex to T 4if the resul t for TSH is abnormal, and urinal ysis) need to be repeated at 
the Day  0Visit. The results of these tests at screening must be reviewed b y the 
investigator prior to initiation of the administration of the IMP. Additional urine and 
blood samples may  be collected for further evaluation of safet y as warranted by the 
investigator’s judgment. Reports from the central laboratory  should be filed with the 
source documents for each subject. The central laboratory  will provide laboratory  results 
to the sponsor electronically .
Any value outside the normal range will be flagged for the attention of the investigat or 
who must indicate whether or not a flagged value is of clinical significance. If one or 
more values are questionable , the test(s) may  be repeated. If the result of any  test (or 
repeat test, if done) is indicated as clinically  significant in the samples taken during the 
screening period, the subject will NOT be enrolled into the trial without the permission of 
the medical monitor. In addition, unscheduled laboratory  tests should be performed if 
clinically  significant abnormalities are observed. Unschedule d laboratory  tests may  be 
repeated at an y time at the discretion of the investigator for appropriate medical care. 
Refer to Appendix 5 (Section 10.5) for criteria for identify ing values of potential clinical 
relevance. Refer to Section 5.2.2 for laboratory  test results that are exclusionary  at 
screening.
The total volume of blood to be collected during the trial isdocumented in the I CF.
A pregnancy  test will be conducted in FOCBP (refer to Section 10.3 for definition) prior 
to trial intervention; results must be available prior to the administration of the IMP. 
Pregnancy  tests can be performed at any
 point during the trial if pregnancy  is suspected.
8.7.2 Physical Examination
Physical examinations will be performed at the time points described in the schedule of 
assessments ( Table 1.3-1 ).
A com plete ph ysical examination will consist of measurement of height and waist 
circumference and a review of the following bod y systems:  head, ey es, ears, nose, and 
throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosa. At 
screen ing, height will be measured with a stadiom eter, measuring stick or tape. Repeat 
measurement of height is not required at the ph ysical examinations schedule d for the 
Protocol 331 -201-00242
53
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Week 1 2or ET visit. Waist circumference will be measured at each ph ysical ex amination 
(screening and Week 1 2or ET), usin g the provided measuring tape. The following 
procedures will aid in the standardization of these measurements:
The subject should be minimally  clothed (ie, lightweight clothing; no heavy  
overgarments).
Waist circumference should be recorded before a subject’s meal and at approximately  
the same time at each visit.
Measurement will be accomplished by  locating the upper hip bone and the top of the 
right iliac crest and placing a weighted measuring tape in a horizontal plane ar ound 
the abdomen at the level of the crest. Before reading the tape measure, the assessor 
should assure that the tape is snug, but does not compress the skin, and is parallel to 
the floor. The measurement is to be made at the end of a normal exhalation.38
The investigator (or designee) is responsible for performing the ph ysical examination. If 
the appointed designee is to perform the ph ysical examination, he or she must be 
permitted by  local regulations and his or her na me must be included on the delegation of 
authority  log. Whenever possible, the same individual should perform all phy sical 
examinations. Any  condition present at the post- treatment phy sical examination that was 
not present at the baseline examination shoul d be documented as an AE and followed to a 
satisfactory  conclusion.
8.7.3 Vital Signs
Vital signs will be collected at the time points described in the schedule of assessments 
(Table 1.3-1 ). Vital sign measurement s scheduled for the same visit as blood samples are 
to be completed before blood is drawn . Subjects should be monitored for potentially  
clinically  significant vital signs values ( Section 10.6).
Vital sign measurements will include body  weight, body  temperature, sy stolic blood 
pressure (SBP), diastolic blood pressure (DBP), and 
heart rate . The following guidelines 
will aid in the standardization of body  weight measurements:
The same scale should be used to weigh a given subject each time, if possible.
Scales should be calibrated and reliable; scales should be at zero just prior to each 
subject’s weigh- in session.
A subject should void prior to being weighed and be minimally  clothed (ie, no shoes 
or heav y overgarments).
Weight should be recorded before a subject’s meal and at approximately  the same 
time at each vis it
.
Protocol 331 -201-00242
54
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Blood pressure and heart rate measurements will be made in the supine and standing 
positions after the subject has been in position for at least 3 minutes. The supine 
measurements will be performed first, followed by standing. 
Subjects with uncontrolled hypertension (screening DBP > 95 mmHg in any  position) or 
symptomatic hy potension at screening or baseline are excluded from the trial as are 
subjects with orthostatic hy potension, which is defined as a decrease of ≥ 30 mmHg in 
SBP or a decrease of ≥20 mmHg in DBP within 3 minutes of standing compared with
the previous supine blood pressure or development of sy mptoms. In addition, subje cts 
should be excluded if they have an y other vital sign measurement at screening or baseline 
that, in the investigator’s judgment, is medicall y significant in that it would impact the 
safet y of the subject or the interpretation of the trial results. Howev er, an y abnormal 
screening or baseline vital sign result(s) considered to be clinically  significant should be 
repeated to confirm the finding(s) before excluding the subject from the trial. 
8.7.4 Electrocardiogram
Electrocardiograms will be performed at the time points described in the schedule of 
assessments ( Table 1.3-1 ). Vital sign and ECG assessments should be completed before 
any blood samples are colle cted. Subjects should be monitored for potentially  clinicall y 
significant ECG results ( Section 10.7).
Electrocardiogram recordings will be obtained after the subject has been supine and at 
rest for at least 5 minutes. Additional ECGs may
 be obtained at the investigator’s 
discretion and should alway s be obtained in the event of an ET. The ECG results will b e 
evaluated at the investigational site to determine the subject’s eligibility  and to monitor 
safet y during the trial. The principal investigator (or qualified designee) will review, sign, 
and date each ECG reading, noting whether or not any  abnormal resul ts are of clinical 
significance. The ECG will be repeated if an y results are considered to be clinically  
significant. A central ECG service will be used for reading all ECGs in order to 
standardize interpretations for the safet y anal ysis.
If during screeni ng, according to the investigator’ s judgment, an y abnormal ECG finding 
is deemed medicall y significant (impacting the safety of the subject or the interpretation 
of the trial results) or meets an exclusion criterion (see Section 5.2.2), the subject should 
be excluded from the trial. Abnormal results for ECGs should be repeated once at 
screening with 3 consecutive ECG recordings to ensure reproducibility  of the 
abnormality  before excluding a subject based on the criteria noted above. Each ECG 
recording should be taken approximately  5 minutes apart (the ECG result reported will be 
evaluated at each time point). The central ECG service will provide the correc tions for 
Protocol 331 -201-00242
55
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020the 3 ECGs performed. Based on the QT interval as corrected for heart rate by  
Fridericia’s formula (QTcF) reported b y the central service, a subject will be excluded if 
the corrections are ≥ 450 msec in men and ≥ 470 msec in women for 2 of the 3 time 
points of the ECGs done, unless due to ventricular pacing. If onl y 1 ECG time point has a 
QTcF of ≥ 450 msec in men and ≥ 470 msec in women, and this is not reproduced at 
either of the other 2 time points, the subject can be included in the trial.
Exclusion criteria for screening do not appl y as mandatory  discontinuation criteria for 
subjects who are alread y randomized. Please consult the medical monitor in case of 
questions.
8.7.5 Suicidality  Monitoring - Columbia-Suicide Severity Rating Scale
Suicidality  monitoring will occur at the time points described in the schedule of 
assessments ( Table 1.3-1 ).
Suicidality  will be monitored during the trial using th e C-SSRS. This trial will use the 
“Baseline/Screening” and “Since Last Visit” versions of the scale. The 
“Baseline/Screening” version, which assesses the lifetime experience of the subject with 
suicide events and suicidal ideation and the occurrence of sui cide events or ideation 
within a specified time period prior to entry into the trial, will be completed for all 
subjects at screening and Day  0 to determine eligibility . Any subject who presents a 
serious risk of suicide should be excluded from the trial(see Section 5.2.2). The “Since 
Last Visit” C
-SSRS form will also be completed at all visits after screening. 
Discussion with the medical monitor during regarding an y concerns or guidance 
regarding the C -SSRS du ring the trial is recommended.
8.7.6 Other Safety  Variables
It is required that an adequately  trained and experienced clinician administer the safet y 
assessments, including the EPS scales (SAS, AIMS, and BARS). The number of raters 
within each trial center shoul d be kept to a minimum. All efforts will be made to ensure 
that the same clinician administers the scales for a given subject. Notations in the 
subject’s trial records should substantiate the ratings. Training and materials for rating 
will be provided by  arater training group.
8.7.6.1 Simpson A ngus Scale
The SAS39consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, 
shoulder shaking, elbow rigidity , wrist rigidity , head rotation, glabella tap, tremor, 
salivation, and akathisia). Each item will be rated on a 5 -point scale, with a score of zero 
Protocol 331 -201-00242
56
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020representing absence of symptoms and a score of 4 representing a severe condition. The 
SAS total score is the sum of the scores for all 10 items. 
Anticholinergics, be nzodiazepines, non-benzodiazepine sleep aids , and propranolol are 
not permitted within 8 hours of scale administration (see Section 6.5.1). Investigators are 
encouraged to delay  scale administration until 8 hours have elapsed, if at all possible. 
However, if delay ing administration of the scale is not feasible, the SAS should still be 
administered and the use of the medication documented, including a notation of the drug 
name, dose, and time of administration on the eS
ource.
8.7.6.2 Abnormal Involuntary Movement Scale
The AIMS27assessment consists of 10 items describing s ymptoms of dy skinesia.  Facial 
and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk 
movements (item 7) will be observed unobtrusively while the subject is at rest (eg, in the 
waiting room), and the investigator will also make global judgments on the subject’s 
dyskinesias (items 8 through 10). Each item will be rated on a 5- point scale, with a score 
of zero representing absence of s ymptoms (for item 10, no awareness), and a score of 4, 
indicating a severe condition (for item 10, awareness, severe distress). For this scale, the 
subject is to be sitting on a hard, firm chair. In addition, the AI MS includes 2 y es or no 
questions that address the subject’s dent al status. 
Anticholinergics, benzodiazepines, non- benzodiazepine sleep aids , and propranolol are 
not permitted within 8 hours of scale administration (see Section 6.5.1). Investigators are 
encouraged to delay  scale administration until 8 hours have elapsed, if at all possible. 
However, if delay ing adminis tration of the scale is not feasible, the AIMS should still be 
administered and the use of the medication documented, including a notation of the drug 
name, dose, and time of administration on the eSource. 
The AIMS Movement Rating Score is defined as the sum of items 1 through 7 (ie, items 
1 through 4, facial and oral movements; items 5 and 6, extremity  movements; and item 7, 
trunk movements).
8.7.6.3 Barnes A kathisia Rating Scale
The BARS40consists of 4 items related to ak athisia:  objective observation of akathisia 
by the investigator, subjective feelings of restlessness by  the subject, subjective distress 
due to akathisia, and global clinical assessment of akathisia. The first 3 items will be 
rated on a 4 -point scale, wit h a score of zero representing absence of s ymptoms and a 
score of 3 representing a severe condition. The global clinical evaluation will be made on 
a 6-point scale, with zero representing absence of sy mptoms and a score of 5 representing 
severe akathisia. To complete this scale, subjects will be observed while they  are seated 
Protocol 331 -201-00242
57
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020and then standing for a minimum of 2 minutes in each position. Sy mptoms observed in 
other situations (eg, while engaged in neutral conversation or engaged in other activity) 
may also b e rated. Subjective phenomena are to be elicited b y direct questioning.  
Anticholinergics, benzodiazepines, non- benzodiazepine sleep aids , and propranolol are 
not permitted within 8 hours of scale administration (see Secti on 6.5.1). Investigators are 
encouraged to delay  scale administration until 8 hours have elapsed, if at all possible. 
However, if delay ing administratio n of the scale is not feasible, the BARS should still be 
administered and the use of the medication documented, including a notation of the drug 
name, dose, and time of administration on the eSource.
8.8 Adverse Events
8.8.1 Definitions
An AE is defined as an y untoward medical occurrence in a clinical trial subject 
administered an IMP and which does not necessarily  have a causal relationship with this 
treatment. Adverse events would not include information recorded as medical history at 
screening for pre -planned procedures for which the underl ying condition was known and 
no worsening occurred. An adverse reaction is any untoward and unintended response to 
an IMP related to an y dose administered.
A suspected adverse reaction is any  AE for which there is a reasonab le possibility  that the 
IMP caused the AE. For the purpose of IND safet y reporting, “reasonable possibility ” 
means there is evidence to suggest a causal relationship between the IMP and the AE. 
Suspected adverse reaction implies a lesser degree of certaint y about causality .
Treatment -emergent AEs are defined as AEs with an onset date on or after the start of 
double -blind treatment. In more detail, TEAEs are all adverse events which started after 
start of double -blind IMP treatment; or if the event was conti nuous from baseline and was 
worsening, serious, IMP related, or resulted in death, discontinuation, interruption or 
reduction of IMP.
An SAE includes an y event that results in any of the following outcomes:
Death
Life-threatening; ie, the subject was, in t he opinion of the investigator, at 
immediate risk of death from the event as it occurred. I t does not include an event 
that, had it occurred in a more severe form, might have caused death.
Persistent or significant incapacity /disability  or substantial disr uption of the 
ability  to conduct normal life functions.
Requires inpatient hospitalization or prolongs hospitalization.
Protocol 331 -201-00242
58
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Hospitalization itself should not be reported as an SAE; whenever possible the 
reason for the hospitalization should be reported.
Hospit alizations or prolonged hospitalizations for social admissions (ie, those 
required for reasons of convenience or other nonmedical need) are not 
considered SAEs.
Prescheduled hospitalization to address a condition that has existed prior to 
the signing of th e ICF should not be considered an SAE.
Congenital anomal y/birth defect.
Other medicall y significant events that, based upon appropriate medical 
judgment, may  jeopardize the subject and may  require medical or surgical 
intervention to prevent one of the outc omes listed above; eg, allergic 
bronchospasm requiring intensive treatment in an emergency  room or home, 
blood dy scrasias or convulsions that do not result in hospitalization, or the 
development of drug dependency  or drug abuse.
Nonserious AEs are all AEs that do not meet the criteria for a “serious ”AE.
Adverse Events of Special I nterest (AESIs) : A noteworthy  event for the particular 
product/IMP or class of products that a sponsor may wish to monitor carefully . All AESIs 
are to be reported as immediatel y reportable events ( IREs).
Immediately  Reportable Event :
Any SAE.
Any AE related to occupational exposure.
Any AESI s (pathological gambling and other compulsive behaviors)
Potential serious hepatotoxicity  (see Section 8.8.6 ).
Pregnancies are also defined as IREs. Although normal pregnancy  is not an AE, it 
will mandate IMP discontinuation and must be reported on a n IRE form and the 
Pregnancy  Surveillance Form(s) to the sponsor. Pregnancy  will only  be 
documented on the AE eSource if there is an abnormality  or complication. This 
includes pregnancy  of the subject or the partner of the subject.
Clinical L aboratory  Test Value Changes: It is the investigator’s responsibility  to review 
the results of laboratory  tests for each individual subject as they  become available. This 
review will be documented by  the investigator’s dated signature on the laboratory  report. 
The inve stigator may  repeat the laboratory  test or request additional tests to verify  the 
results of the original laboratory tests. If this laboratory  value is considered medically  
relevant (ie, clinicall y significant) b y the investigator (subject is symptomatic, requiring 
corrective treatment or further evaluation), or if the laboratory  value leads to 
discontinuation, and/or fulfills a seriousness criterion, this is considered an AE. 
Protocol 331 -201-00242
59
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Severity : Adverse events will be graded on a 3- point scale and reported as indic ated on 
eSource . The severity  of an adverse experience is defined as follows:
1 = Mild: Discomfort noticed, but no disruption to daily  activity .
2 = Moderate: Discomfort sufficient to reduce or affect normal daily  activit y.
3 = Severe: Inability  to work or perform normal daily  activity .
IMP Causalit y: Assessment of causal relationship of an AE to the use of the IMP is 
defined as follows:
Related : There is a reasonable possibility  of a temporal and causal 
relationship between the IMP and the AE.
Not Relate d: There is no temporal or causal relationship between the I MP and 
the AE.
8.8.2 Eliciting and Reporting A dverse Events
The investigator will regularly  assess subjects for the occurrence of AEs. To avoid bias in 
eliciting AEs, subjects should be asked the non leading question: “How have y ou felt 
since y our last visit?” AllAEs (serious and nonserious) reported b y the subject must be 
recorded on the source documents and eSource provided by  the sponsor. Adverse event 
collection will begin after a subject signs th e ICF.
Medical terminology  should be used for AE reporting. Adverse events should be reported 
as a single unify ing diagnosis whenever possible or, in the absence of a unify ing 
diagnosis, as individual signs or s ymptoms.
Exacerbation or disease progression should be reported as an AE onl y if there are 
unusual or severe clinical features that were not present, or experienced earlier, or not 
expected based on the course of the condition. 
In addition, the sponsor must be notified immediately b y telephone, fax, or e-mail of an y 
IREs according to the procedure outlined below, in Section 8.8.3. Special attention 
should be pa id to recording hospitalization and concomitant therap y
.
Adverse event, s tart date, end date , seriousness, s everity , relationship to trial treatment
(IMP Causality ), action taken with trial treatment and outcome will be recorded on the 
source documents and in eSource .
8.8.3 Immediately  Reportable Events
The investigator must immediately  report (within 24 hours), using an IRE form, after 
he/she or site personnel become aware of an y IRE (SAE, AE related to occupational 
Protocol 331 -201-00242
60
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020exposure, AESI , potential serious hepatotoxicity , or confirmed pregnancy ), by telephone, 
fax, or e- mail to the sponsor or designee using the contact information on the cover page 
of this protocol (Please note that the I RE form is NOT the AE eSource .).
8.8.4 Medical Device Incidents (Including Malfunctions)
Not applicable.
8.8.5 Adverse Events of Special Interest
The new onset or exacerbation of “Pathological Gambling and Other Compulsive 
Behaviors” will be analyzed as an AESI.
8.8.6 Potential Serious Hepatotoxicity
For a subject who experiences an elevatio n in AST or ALT that is  3 times the ULN , a 
total bilirubin level should also be evaluated. If the total bilirubin is 2 times the ULN, 
complete an IRE form with all values listed and also report as an AE on eSource .
8.8.7 Procedure for Breaking the Blind
The investigator is encouraged to contact the sponsor/Clinical Research Organization 
(CRO) medical monitor to discuss their rationale for unblinding. However, to prevent 
delay s to the investigator or medical personnel responding to a potentiall y emergent 
situa tion, unblinding of IMP will not be dependent upon the investigator receiving 
approval from the sponsor/CRO medical advisor (ie, the investigator will be able to 
obtain the code break information independent of the sponsor/CRO medical advisor). The 
investi gator must contact the sponsor/CRO medical advisor b y telephone or e -mail with 
an explanation of the need for opening the treatment assignment code within 24 hours of 
opening the code. If the blind is broken, the Global Pharmacovigilance Department must 
benotified immediately  (see the cover page of this protocol for contact information). 
Documentation of breaking the blind should be recorded in the subject’s medical record 
with the date and time the blind was broken and the names of the personnel involved.
Once the blind is broken for a subject, that subject may  not reinitiate treatment with the 
IMP.
8.8.8 Follow -up of A dverse Events
8.8.8.1 Follow -
up of Nonserious A dverse Events
Nonserious AEs that are identified at an y time during the trial must be recorded on the 
AE eSource with the current status (ongoing or resolved/recovered) noted. All nonserious 
events (that are not IREs) that are ongoing at the last scheduled contact will be recorded 
as ongoing on eSource . For any  AE having been identified throughout the trial, during 
Protocol 331 -201-00242
61
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020analysis, additional relevant medical history  information may  be requested by  the sponsor 
to further ascertain causality  (including, but not limited to, information such as risk -
related behavior, family  history  and occupation).
8.8.8.2 Follow -up of Immediat ely Reportable Events
This trial requires that subjects be activel y monitored for IREs up to 21 day s after the last 
dose of IMP is administered.
Immediately  reportable events that are identified or ongoing at the last scheduled 
contact must be recorded as 
such on the AE eSource page and the IRE form. I f updated 
information (eg, resolved status) on IRE status becomes available after a subject’s last 
scheduled contact (up to last in- clinic visit for the entire trial), this must be reported to the 
sponsor and recorded on the AE eSource page and the I RE form, according to the 
appropriate reporting procedures described in Section 8.8.3.
It is expected that the investigator will provide or arrange appropriate supportive care for 
the subject and will provide prompt updates on the subject’s status to the sponsor. The 
investigator will follow IREs until the events are:
resolved,
stabilized,
the subject is lost t o follow -
up, or
has died.
Resolution means that the subject has returned to the baseline state of health and 
stabilized means that the investigator does not expect an y further improvement or 
worsening of the subject’s condition. The investigator will cont inue to report any  
significant follow -up information to the sponsor up to the point the event has resolved or 
stabilized, or the subject is lost to follow -up, or has died.
Refer to Section 10.3 for additional information regarding the follow-up period for 
subjects that become pregnant or for pregnant partners of male subjects.
8.8.8.3 Follow -up and Reporting of Immediately Reportable Events 
Occurring A fter Last Scheduled Contact
Any new IREs reported to the investigator which occur after the last scheduled contact
and are determined b y the investigator to be reasonably associated with the use of the 
IMP, should be reported to the sponsor according to the procedures outlined in 
Section 8.8.3. This may  include IREs that are captured on follow -up telephone contact or 
at an y other time point after the defined trial period and continue to report any significant 
Protocol 331 -201-00242
62
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020follow -up informatio n to the sponsor until the events are resolved or stabilized, or the 
subject is lost to follow -up or has died.
8.9 Treatment of Overdose
For treatment of overdose, please refer to IB Section 6.3, Overdosage. 
8.10 Subject A ssessment Recording
Subject assessment rec ordings are included under efficacy  assessments in Section 8.1.
8.11 Other A ssessments
Not applicable.
9 Statistical Considerat ions
Complete details of the planned statistical anal ysis will be presented in the statistical 
analysis plan (SAP).
9.1 Sample Size
Approximately  240 subjects will be enrolled in the trial.  
9.2 Datasets for A nalysis
The following anal ysis samples are defined for this trial:
Enrolled Sample: comprises all subjects who signed an ICF for the trial and enrolled into 
the trial on Day  0.
Safety  Sample: comprises those randomized subjects in the double -blind treatment period 
who received at least 1 dose of double -blind IMP as indicated on the dosing record. 
Intent -to-treat:
Sample:comprises all subjects in the Safet y Sample who have 
measurements of ZAN -BPD total score before randomization and at least 1 post-
randomization time point .
9.3 Handling of Missing Data for Primary and Key  Secondary  Endpoint 
Analysis
.

Protocol 331 -201-00242
63
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20209.4 Statistical A nalyses
9.4.1 Efficacy  Analyses
9.4.1.1 Primary  Efficacy  Endpoint A nalysis
The prim ary efficacy  analy sis will be performed by  fitting a mixed -effect model repeated 
measure (MMRM) anal ysis with an unstructured variance covariance structure in which 
the change from the baseline in ZAN -BPD total score during the double- blind treatment 
perio d will be the dependent variable based on the observed cases data set. The model 
will include fixed class effect terms for treatment, trial site, visit week, and an interaction 
term of treatment b y visit week. The model will also include the interaction te rm of 
baseline values of ZAN -BPD total score b y visit week as covariates. All scheduled visits 
after baseline during the double- blind treatment period will be included in the model.
 
9.4.1.2 Key Secondary  Efficacy  Endpoint Analysis
The key  secondary  efficacy  endpoint will be anal yzed by  fitting the same MMRM model 
described i n the primary  anal ysis. 
9.4.1.3 Secondary  Efficacy Endpoint Analysis
9.4.1.4 Control of Experiment -wise Ty pe 1 Error
9.4.2 Safety  Analysis
Standard safet y variables to be anal yzed include AEs, clinical laboratory  tests, vital signs, 
ECGs, and phy sical examinations. I n addition, data from the following safety  scales will 
be evaluated:  assessments of suicidality  (C-SSRS) and EPS (eg, the SAS, AI MS, and 
BARS). Safet y anal ysis will be conducted based on the Safet y Sample defined in 
Section 9.2. I n general, baseline of a safet y variable is defined as the last observation of 
the variable before taking the first dose of IMP, unless specified otherwise. Pr ospectively  
defined criteria will be used to identify  potentiall y clinically  relevant abnormal values for 
clinical laboratory  tests, vital signs, ECGs, and body  weight. Details of safety  anal yses 
will be provided in the SAP.

Protocol 331 -201-00242
64
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20209.4.2.1 Adverse Events
All AEs will be coded b y system organ class and Medical Dictionary  for Regulatory  
Activities preferred term. The incidence of the following events will be summarized by  
treatment group:
TEAEs
TEAEs by  severit y
TEAEs potentially  causally  related to the IMP
TEAEs with an ou tcome of death
Serious TEAEs
TEAEs leading to discontinuation of the I MP 
AESI
9.4.2.2 Clinical Laboratory  Data
Summary  statistics for changes from baseline in the routine clinical laboratory  
measurements and prolactin c
oncentrations will be provided. In addition, the incidence of 
potentially  clinicall y relevant values identified using prospectivel y defined in the SAP 
criteria for laboratory tests will be summarized.
9.4.2.3 Physical Examination and Vital Signs Data
Physical examination findi ngs will be listed by  subject. Potentially  clinically  relevant 
results in vital signs and body  weight will also be summarized.
Summary  statistics for change from baseline in vital signs, bod y weight, and waist 
circumference will be provided.
9.4.2.4 Electrocardiog ram Data
Mean change from baseline will be summarized by  visit.
The incidence of clinically relevant changes will be calculated for ECG parameters and 
summarized by  visit.
For the anal ysis of QT and corrected QT interval (QTc)data from 3 consecutive 
compl exes (representing 3 consecutive heart beats) will be measured to determine 
average values. The following QT corrections will be used:
1) QTcB is the length of the QT interval corrected for heart rate b y the Bazett’s formula:
QTcB=QT/(RR)0.5, and
2) QTcF i s the length of the QT interval corrected for heart rate b y the Fridericia formula:
Protocol 331 -201-00242
65
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020QTcF=QT/(RR)0.33
3) QTcN is the length of the QT interval corrected for heart rate b y the Food and Drug 
Administration ( FDA )Neuropharm Division formula: 
QTcN=QT/(RR)0.37
Results will be summarized by  visit.
9.4.2.5 Other Safety  Data
Change from baseline in scores for EPS (eg, SAS, AI MS, and BARS) will be evaluated 
using descriptive statistics. The anal yses will be based on the observed case (OC) and last 
observation carried forwar ddatasets of the Safet y Sample.
Suicidality  (eg, C -SSRS) will be summarized by  treatment group by  descriptive statistics. 
Details will be described in SAP.
9.4.3 Other A nalyses
9.4.3.1 Analysis of Demographic and Baseline Characteristics
Baseline demographic characteri stics including age, race, ethnicit y, gender, weight, 
height, and BMI will be summarized by  descriptive statistics (frequency , mean, median, 
standard deviation, maximum, minimum, and percentage when applicable).
9.4.3.2 Pharmacokinetic A nalysis
Pharmacokinetic sam ples will be anal yzed for brexpiprazole (OPC -34712) and its 
metabolite(s) and descriptive statistics will be calculated. No formal statistical 
comparisons are planned. 
9.4.3.3 Pharmacody namic Analy sis
Not applicable .
 
 

Protocol 331 -201-00242
66
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul20209.5 Interim A nalysisand A daptiv e Design
No interim anal ysis or adaptive design are planned .
9.5.1 Data Monitoring Committee
Not applicable.
Protocol 331 -201-00242
67
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202010 Supporting Documentation and Operational Considerations
10.1 Appendix 1: Regulatory , Ethical, and Trial Oversight 
Considerations
10.1.1 Ethics and Responsibility
This trial must be conducted in compliance with the protocol, Food and Drug 
Administration ( FDA )regulations ,International Conference for Harmonis ation ( ICH)
GCP: Consolidated Guideline (E6 [R2]), international ethical principles derived from the 
Declaration of Helsinki and Council for International Organizat ions of Medical Science 
guidelines, and applicable local laws and regulations. Each trial sit e will seek 
approval/favorable opinion by  an IRB or IEC according to regional requirements, and the 
investigator will provide that documentation to the sponsor. The IRB/IEC will evaluate 
the ethical, scientific and medical appropriateness of the trial. Fur ther, in preparing and 
handling eSource , the investigator, sub investigator and their staff will take measures to 
ensure adequate care in protecting subject privacy . To this end, a subject ID will be used 
to identify  each subject.
Financial aspects, subject insurance and the publication policy  for the trial will be 
documented in the agreement between the sponsor and the investigator.
10.1.2 Informed Consent
Informed consent will be freel y obtained from all subjects (or their guardian or legally 
acceptable representative, as applicable for local laws). The electronic ICFwill be 
approved b y the same IRB/IEC that approves this protocol. 
Each ICF will comply  with the I CH GCP : Consolidated Guideline E6(R2)41and local 
regulatory  requirements. The investigator will ensure that the sponsor reviews and 
authorizes any  written site -specific ICF used in the trial before submission to the 
IRB/IEC. 
Investigators may discuss trial availability  and the possibility  for entry  with a potential 
subject without first obtaining consent. However, informed consent must be obtained and 
documented before initiation of any  procedures that are performed solel y for the purpose 
of determining eligibility  for this trial, including withdrawal from current med ication(s). 
Potential subjects are free to refuse entry  into the trial, or withdraw from the trial at any  
time, without justification, and there will be no consequences to their further care.
Prospective trial subjects will be provided with controlled access to the electronic ICF 
application by  trial site staff. When the trial site staff and the subject agree that the 
Protocol 331 -201-00242
68
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020subject has enough information to make an informed decision to participate, t he subject 
will electronicall y sign in the electronic ICF application and an electronic date and 
timestamp will be applied to the signature. The subject will be given a printed, signed 
copy  of the ICF. Any  other parties required b y the I RB/IEC (trial site staff, witnesses, or 
legally  authorized representative) are also required to sign electronicall y and these 
signatures will be stored with the electronic ICF in accordance with the ICH GCP 
Guideline and local regulatory requirements/guidelines. These signatures cannot be 
altered, removed, or copied.
Once appropriate essential information has been provided and full y explained in 
layman’s language to the subject by  the investigator (or a qualified designee), and it has 
been documented that the subject has had the op portunity  to ask questions, the
IRB/IEC -approved written ICF will be signed and dated by  both the subject and the 
person obtaining consent (investigator or designee), as well as b y any other parties 
required b y the IRB/IEC. The subject will receive a copy of the signed ICF; the original 
shall be kept on file b y the investigator.
Subjects may  be asked to sign additional ICFs if the protocol is amended and the changes 
to the protocol results in additional information that needs to be provided to the subjects, 
so that they  can make a knowledgeable and voluntary  decision on continued trial 
participation. Female partners of male subjects who become pregnant during the course 
of the trial may be asked to sign additional I CFs in order to collect additional information 
regarding the nonsubject partner and fetus.
 
 
10.1.3 Confidentiality
All information generated in this trial will be considered confidential and will not be 
disclosed to any one not directly  concerned with the trial without the sponsor’s prior 
written permission. Subject confidentiality requirements of the region(s) where the trial is 
conducted will be met. However, authorized regulatory officials and spons or personnel 
(or their representatives) may  be allowed full access to inspect and copy  the records, 
consistent with local requirements. All I MPs, subject bodily  fluids, and/or other materials 
collected shall be used solely  in accordance with this protocol, unless otherwise agreed to 
in writing b y the sponsor.

Protocol 331 -201-00242
69
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Subjects will be identified only  by unique subject ID in eSource . If further subject 
identification is required, subjects’ full names may be made known to a regulatory  
agency  or other authorized offici als if necessary , subject to local regulations.
10.1.4 Quality  Control and Quality  Assurance
10.1.4.1 Monitoring
The sponsor has ethical, legal, and scientific obligations to follow this trial in accordance 
with established research principles, the ICH GCP: Consolidated G uideline (E6 [R2]), and 
applicable regulatory  requirements and local laws. As part of a concerted effort to fulfill 
these obligations (maintain current personal knowledge of the progress of the trial), the 
sponsor ’s monitors will visit the site during the trial, as well as communicate frequently  
via telephone, e -mail, and written communications. I n addition, all investigators and trial 
site personnel will undergo initial and ongoing training for this particular trial, and this 
training will be clearl y docume nted.
10.1.4.2 Auditing
The sponsor ’s Qualit y Assurance Unit (or representative) may conduct trial site audits. 
Audits will include, but are not limited to, I MP supply , presence of required documents, 
the informed consent process, and a review of eSource with sourc e documents, as 
applicable. The investigator agrees to participate with audits.
Regulatory  authorities may  inspect the investigator site during or after the trial. The 
investigator will cooperate with such inspections and will contact the sponsor 
immediate ly if such an inspection occurs.
10.1.5 Protocol Deviations
In the event of a significant deviation from the protocol due to an emergency, accident, or 
mistake (eg, violation of informed consent process, I MP dispensing or subject dosing 
error, treatment assignmen t error, subject enrolled in violation of eligibility  criteria or 
concomitant medication criteria), the investigator or designee will contact the sponsor or 
designee at the earliest possible time by  telephone or via e -mail. The investigator and 
sponsor (or designee) will come as quickl y as possible to a joint decision regarding the 
subject’s continuation in the trial. This decision will be documented b y the investigator 
and the sponsor (or designee) and reviewed b y the site monitor.
Any major protocol devia tion will be recorded in eSource along with the start date and 
details of the deviation.
Protocol 331 -201-00242
70
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202010.1.6 Records Management
10.1.6.1 Source Documents
Source documents are defined as the results of original observations and activities of a 
clinical investigation. Source documents will include but are not limited to medical 
records, electronic data, screening logs, and recorded data from automated instruments. 
All source documents pertaining to this trial will be maintained b y the investigators and 
made available for direct inspection by  authorized persons.
Investigator(s)/institution(s) will permit trial- related monitoring, audits, I RB/IEC review, 
and regulatory  inspection(s) by  providing direct access to source data/documents by  
authorized persons as defined in the I CF. In all cases , subject confidentiality  must be 
maintained in accordance with local regulatory  requirements.
10.1.6.2 Data Collection
During each subject’s visit to the site or remote visit, an investigator or their designee 
participating in the trial will record information to 
document all significant observations. 
At a minimum, these notes will contain:
Documentation of the informed consent process, including an y revised consents;
Documentation of the investigator’s decision to enroll the subject into the trial, 
the review of all inclusion/exclusion criteria prior to I MP administration, and 
confirmation of the subject’s actual participation in the trial;
The date of the visit and the corresponding Visit or Day  in the trial schedule;
General subject status remarks, including an ysignificant medical findings. The 
severit y, frequency, duration, action taken, and outcome of an y AEs and the 
investigator ’s assessment of relationship to I MP must also be recorded;
Any changes in concomitant medications or dosages;
A general reference to the procedures completed; 
The signature (or initials) and date of the investigator (or designee) who made an 
entry  in the medical record.
In addition, any  contact with the subject via telephone or other means that provides 
significant clinical informati on will also be documented in the progress notes as 
described above.
Source documents and source data will be captured electronically  (where permitted by  
local regulation) in this trial and will meet the same fundamental elements of data qualit y 
(eg, attributable, legible, contemporaneous, original, and accurate) as paper records. 
Protocol 331 -201-00242
71
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020These data will be collected into a sy stem that is fully  validated according to 21 CFR 
Part11. Changes to the data will be captured b y an automatic audit trail.
Designated trial site staff will not be given access to the electronic source sy stem until 
they have been appropriately  trained. Information to be originall y captured and reviewed 
electronically  shall include details of the subject visit and the protocol required 
assessments performed as a part of these visits, medical history , AEs, and concomitant 
medications. Because this trial is using an electronic source record as the original point of 
data capture, there is no additional data entry  step for the trial site for d ata collected 
directly  into the application, rather, the electronic source record directl y populates the 
trial database.
Some data may  be captured via paper and then entered into the eSource s ystem. These 
and an y other data treated in this manner will be s ource data verified per the monitoring 
plan and the location of the source data (ie, eSource, paper, or a local electronic sy stem) 
will be documented before the trial start. An y changes to information in paper source 
documents will be initialed and dated o n the day  the change is made by a trial site staff 
member authorized to make the change. Changes will be made b y striking a single line 
through erroneous data (so as not to obliterate the original data), and clearly entering the 
correct data (eg, wrong dat aright data). If the reason for the change is not apparent, a 
brief explanation for the change will be written in the source documentation by  the 
investigator or their designee.
Another exception will be safet y laboratory  (or central ECG data) , where the official 
source documentation will be considered the report issued by  the anal yzing laboratory .
Remote monitoring of the original electronic source records will take place ;however ,
on-site monitoring inspections will continue to take place in order to rev iew data entry  of 
source documentation directly  captured on paper and transcribed into the s ystem, to 
ensure protocol adherence, to assess trial site operational capabilities and to perform 
other monitoring activities that cannot be performed remotely
.
At the end of the trial, the investigator must certify that the data entered into the eSource 
application are complete and accurate. After database lock, the investigator will receive 
an electronic cop
y of the subject data.
10.1.6.3 File Management at the Trial Site
The investigator will ensure that the trial site file is maintained in accordance with 
Section 8 of the I CH GCP: Consolidated Guideline (E6 [R2]) and as required by 
applicable local regulations. The investigator/institution will take measures to prevent 
accidental or premature destruction of these documents.
Protocol 331 -201-00242
72
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202010.1.6.4 Records Retention at the Trial Site
Regulatory  requirements for the archival of records for this trial necessitate that 
participating investigators maintain detailed clinical data for the longest of the f ollowing 
3 periods:
A period of at least 2 years after the date on which approval to market the drug is 
obtained (or if IMP development is discontinued, the date regulatory  authorities were 
notified of discontinuation); OR
A period of at least 3 y ears afte r the sponsor notifies the investigator that the final 
report has been filed with regulatory  authorities.
Longer, region -specific storage requirements, if applicable. 
The investigator must not dispose of an y records relevant to this trial without either 
(1)written permission from the sponsor or (2) provision of an opportunity  for sponsor to 
collect such records. The investigator will be responsible to maintain adequate and 
accurate electronic or hard copy source documents of all observations and data gene rated 
during this trial including any  data clarification forms received from the sponsor. Such 
documentation is subject to inspection by  the sponsor and relevant regulatory  authorities. 
If the investigator withdraws from the trial (eg, due to relocation or retirement), all 
trial-related records should be transferred to a mutually  agreed -upon designee within a 
sponsor -specified timeframe. Notice of such transfer will be given to the sponsor in 
writing.
10.1.6.5 Publication A uthorship Requirements
Authorship for an y Otsuka -sponsored publications resulting from the conduct of this trial 
will be based on International Committee of Medical Journal Editors (I CMJE) authorship 
criteria (http://www.icmje.org/recommendations). According to ICMJE guidelines, one 
may be consider ed an author only  if the following criteria are met:
1)Substantial contributions to the conception or design of the work; or the 
acquisition, analy sis, or interpretation of data for the work; AND
2)Drafting the work or revising it criticall y for important intellectual content; AND
3)Final approval of the version to be published; AND
4) Agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy  or integrit y of an y part of the work are appropriately 
investigated and resolved.
All authors must meet the above criteria, and all who qualify  for authorship based on the 
above criteria should be listed as authors.
Protocol 331 -201-00242
73
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Investigators or other trial subjects who do not qualify  for authorship may  be 
acknowledged in publications res ulting from the trial. By  agreeing to participate in the 
trial, investigators or other trial subjects consent to such acknowledgement in any  
publications resulting from its conduct.
Protocol 331 -201-00242
74
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202010.2 Appendix 2: Clinical Laboratory  Tests
The tests detailed in Table 10.2-1 w ill be performed.
Table 10.2-1 Clinical Laboratory Assessments
Hem atology:
Hem oglobin
Hem atocrit
MCH
MCHC
MCV
Platelet count 
RBC count
RBC morphology
RDW
WBC count with differential 
Urinalysis:
Specimen Appearance
Color 
Occult Blood
Glucose
Microscopic analysis, WBC/RBC counts per high 
powered field
pH
Protein
Specific Gravity
Ketones
Urine Drug Screens:
Amphetamines/MDMA
Barbiturates
Benzodiazepines
Cannabinoids
Cocaine
Methadone
Opiates
Phencyclidine
Propoxyphene
Drug and Alcohol Screening
Blood alcoholSerum Chemistry:
ALP
ALT
AST
Bilirubin , total
BUN
Calcium
Cholesterol (total, LDL, and HDL)
CPK
Creatinine
GGT
Glucose
Lactic Dehydrogenase
Magnesium
Potassium
Prolactina
Protein , total
Sodium
Triglycerides
Uric acid
Additional Tests:
Urine and serum pregnancy for FOCBPb
TSH, w ith reflex to free T 4if TSH is abnormal
Prothrombin time , Activated pa rtial 
thromboplastin time, and Inte rnational 
norm alized ratio (screening only)
HbA 1c
Additional Tests (screening only):
HIV
HBsAg
Anti-HCV
ALP = alkaline phosphatase; anti-HCV = hepatitis C antibodies; BUN =blood urea nitrogen; 
GGT =gamma glutamyl transferase; HBsAg = hepatitis B surface antigen; HDL = h igh density 
lipoprotein; LDH =lactic dehydrogenase; LDL = low density lipoprotein; MCH = mean corp uscular 
hemoglobin ; MCHC = m ean corpuscular hemoglobin concentration; MCV = mean corpuscular 
volume; MDMA = methylenedioxymethamphetamine; RBC = red blood cell; RDW = red cell 
distribution width; WBC = white blood cell.
aProlactin results will be blinded to the investigators and trial staff.
bAll positive urine pregnancy test results must be confirmed by a serum test. Subjects w ith a positive 
serum pregnancy test result at screening must not be enrolled and subjects with a positive serum 
pregnancy test result during the trial must discontinue treatment and be withdrawn from the trial.
Protocol 331 -201-00242
75
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202010.3 Appendix 3: Contraceptive Guidance and Collection of Pregnancy  
Information
Females of child- bearing poten tialare females whose menstruation has started and who 
are not documented as sterile (eg, have had a bilateral oophorectom y, or h ysterectom y, or 
who have been postmenopausal for at least 12 months).
For males and FOCBP, who are sexually  active, there must be a documented agreement 
that the subject and their partner will take effective measures (ie, 2different approved 
methods of birth control or remains abstinent) to prevent pregnancy  during the course of 
the trial and for 30daysafter the last dose of IMP. Unless the subject is sterile (ie, 
females who have had a bilateral oophorectomy , have had a hy sterectomy , or have been 
postmenopausal for at least 12 consecutive months; or males who have had a bilateral 
orchidectom y) or remains abstinent during the t rial and for 30days after the last dose of 
IMP, 2 of the following approved methods of birth control must be used: vasectomy , 
tubal ligation, intrauterine device, birth control pills, birth control implant, birth control 
depot injection, condom with spermicide, sponge with spermicide, or occlusive cap 
(vaginal diaphragm or cervical/vault cap) with spermicide. 
Any single method of birth control, including vasectomy  and tubal ligation, may  fail,
leading to pregnancy . The contraceptive method will be documen ted in eSource. 
Abstinence is defined as refraining from heterosexual intercourse during the entire period 
of risk associated with the trial treatments. The reliability  of sexual abstinence should be
evaluated in relation to the duration of the clinical tr ial and the preferred and usual 
lifesty le of the subject. Consensual sexual activity that cannot biologically  result in 
pregnancy  may  not be subject to required birth control methods, following disc ussion 
with the medical monitor
. The contraceptive method will be documented in eSource . 
Male subjects must also agree not to donate sperm from trial screening through 30days
after the last dose of IMP.
Before enrolling males and females in this clinical trial, investigators must review the 
below information about trial participation as part of the I CF process. The topics should 
generall y include:
General information
Informed consent form
Pregnancy  prevention information
Drug interactions with hormonal contraceptives
Contraceptives in current use
Follow -up of a reported pregnancy
Protocol 331 -201-00242
76
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Before trial enrollment, males and FOCBP must be advised of the importance of avoiding 
pregnancy  during trial participation and the potential risk factors for an unintentional 
pregnancy . Subjects must sign the ICF confirming that the above -mentioned risk factors 
and the consequences were discussed.
A urine or serum pregnancy  test for human chorionic gonadotropin will be performed at 
screening on all FOCBP. If a urine test is performed and is positive, the investigator will 
follow -up wi th a confirmatory  serum test.
During the trial, all FOCBP should be instructed to contact the investigator immediately  
if they  suspect they  might be pregnant (eg, missed or late menstrual cycle). Male subjects 
must be instructed to contact the investigator immediatel y, during the trial, if their partner 
suspects that they  might be pregnant (eg, missed or late menstrual cy cle).
If a subject is suspected to be pregnant before she receives IMP, the IMP administration 
must be withheld until the results of serum pregnancy  tests are available. If the pregnancy  
is confirmed, the subject must not receive the IMP and must not be enrolled in the trial. If 
pregnancy  is suspected while the subject is taking IMP, the IMP must be withheld 
immediately  (if reasonable, takin g into consideration any  potential withdrawal risks) until 
the result of the pregnancy test is known. If pregnancy  is confirmed, the I MP will be 
permanentl y discontinued in an appropriate manner (eg, dose tapering if necessary for 
subject safet y) and the s ubject will be withdrawn from the trial. Exceptions to trial 
discontinuation may  be considered for life -threatening conditions only  after consultations 
with the I RE contact (see the title page of this protocol for contact information).
The investigator mus t immediately  notify  the sponsor (within 24 hours) of any  pregnancy  
associated with IMP exposure during the trial and for at least 30days after the last dose 
of IMP, and record the event on the I RE form and forward it to the sponsor. The sponsor 
will forw ard the Pregnancy  Surveillance Form(s) to the investigator for monitoring the 
outcome of the pregnancy.
Protocol required procedures for trial discontinuation and follow -up must be performed 
on the subject unless contraindicated b y pregnancy (eg, x -ray studies). Other appropriate 
pregnancy  follow -up procedures should be considered if indicated. In addition, the 
investigator must report to the sponsor, on the Pregnancy  Surveillance Form(s), follow -
up information regarding the course of the pregnancy , includi ng perinatal and neonatal 
outcome. Infants will be followed for a minimum of 6 months from the date of birth. 
Protocol 331-201-00242
77
Confidential - Proprietary Information Amendment 1 Approval: 07 Jul 202010.4 Appendix 4: Abbreviations
Abbreviation Definition
5-HT Serotonin
AAD Agitation in Alzheimer’s diseaseADHD Attention-deficit/hyperactivity disorderADT Antidepressant therapyAE Adverse eventAESI Adverse event of special interestAIMS Abnormal Involuntary Movement ScaleALT Alanine aminotransferaseALP Alkaline phosphataseanti-HCV Hepatitis C antibodiesaPTT Activated partial thromboplastin timeAST Aspartate aminotransferaseBARS Barnes Akathisia Rating ScaleBMI Body mass indexBPD Borderline personality disorderBPM Beats per minuteBUN Blood urea nitrogenCGI-I Clinical Global Impression-Improvement of Illness
CGI-S Clinical Global Impression-Severity of Illness
CPK Creatine phosphokinase
CRO Contract research organizationC-SSRS Columbia-Suicide Severity Rating Scale
CYP Cytochrome P450
D DopamineDBP Diastolic blood pressureDNA Deoxyribonucleic acidDSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th editionDSM-5 Diagnostic and Statistical Manual of Mental Disorders, 5th editionECG ElectrocardiogramEPS Extrapyramidal symptomsET Early terminationFBR Future Biospecimen ResearchFDA Food and Drug AdministrationFOCBP Females of childbearing potentialGCP Good Clinical PracticeGGT Gamma-glutamyl transferase
HbA
1c Glycosylated hemoglobin
HBsAg Hepatitis B surface antigen
HDL High-density lipoproteinHIV Human immunodeficiency virusCCI
Protocol 331 -201-00242
78
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Abbreviation Definition
ICF Informed consent form
ICH International Council for Harmonisation
ICMJE International Committee of Medical Journal Editors
IEC Independent Ethics Committee
IMP Investigational medicinal product(s)
IND Investigational New Drug
INR International normalized time
IRB Institutional Review Board
IRE Immediately  reportable event
Ki Inhibitory  constant
LDH Lactate deh ydrogenase
LDL Low-densit y lipoprotein
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
MDD Major depressive disorder
MDMA Methylenedioxy methamphetamine
MINI Mini I nternational Neuropsy chiatric Interview
MMRM Mixed -effect model repeated measure
OC Observed case
OPDC Otsuka Pharmaceutical Development & Commercialization, I nc 
PGI-C Patient’s Global I mpression of Change
PGI-S Patient’s Global I mpression of Severit y
PGx Pharmacogenomic(s)
PK Pharmacokinetic(s)
PQC Product Quality  Complaint
PT Prothrombin time
PTSD Post-traumatic stress disorder
QTcB QT interval as corrected by  Bazett’s formula
QTcF QT interval as corrected by  Fridericia’s formula
QTcN QT interval as corrected by  the FDA Neuropharm Division formula
RBC Red blood cell
RNA Ribonucleic acid
RR Response rate
SAE Serious adverse event
SAP Statistical analy sis plan
SAS Simpson Angus Scale
SBP Systolic blood pressure
SCID-5- PD Structured Clinical Interview for DSM -5 Personality  Disorders
SYE Subject y ears of exposure
T4 Thyroxine
TEAE Treatment -emergent adverse event
TSH Thyroid- stimulating hormone
ULN Upper limit of normal
US United States
WBC White blood cell
Protocol 331 -201-00242
79
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Abbreviation Definition
ZAN -BPD Zanarini Rating Scale for Borderline Personalit y Disorder

Protocol 331 -201-00242
80
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202010.5 Appendix 5: Criteria for Identify ing Laboratory Values of Potential 
Clinical Relevance
Laboratory Tests Criteria
Chemistry
AST (SGOT) 3 xULN
ALT (SGPT) 3 xULN
Alkaline phosphatase 3 xULN
Lactate dehydrogenase 3 xULN
Blood urea nitrogen 30mg/d L
Creatinine 2.0mg/d L
Uric acid
Men 10.5 mg/dL
Wom en 8.5mg/d L
Bilirubin (total) 2.0mg/d L
Creatine phosphokinase > 3 x ULN
Prolactin > ULN
Hem atology
Hem atocrit
Men 37 % and decrease of 3 percentage points from baseline
Wom en 32 % and decrease of 3 percentage points from baseline
Hem oglobin
Men 11.5 g/dL
Wom en 9.5 g/dL
WBC count 2,800 mm3 or 16,000 mm3
Eosinophils 10%
Neutrophils 15%
Absolute neutrophil count 1,500/mm3
Platelet count 75,000/mm3or 700,000/mm3
Urinalysis
Protein Increase of 2 units
Glucose Increase of 2 units
Casts Increase of 2 units
Additional Criteria
Chloride 90 mEq/L or 118 mEq/L
Potassium 2.5 mEq/L or 6.5 mEq/L
Sodium 126 mEq/L or 156 mEq/L
Calcium 8.2mg/d L or 12mg/d L
Glucose
Fasting 100mg/dL
Nonfasting 200mg/dL
Total cholesterol, fasting 240mg/dL
LDL cholesterol, fasting 160mg/dL
HDL cholesterol, fasting
Men < 40 mg/dL
Wom en < 50 mg/dL
Triglycerides, fasting 150mg/d L
Protocol 331 -201-00242
81
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202010.6 Appendix 6: Criteria for Identify ing Vital Signs of Potential Clinical 
Relevance
Variable Criterion ValueaChange Relative to 
Baselinea
Heart rateb > 120 bpm
< 50 bpm15 bpm increase
15 bpm decrease
Systolic blood pressureb > 180 mmHg
< 90 mmHg20 mmHg increase
20 mmHg decrease
Diastolic blood pressureb > 105 mmHg
< 50 mmHg15 mmHg increase
15 mmHg decrease
Orthostatic hypotension20 mmHg decrease in systolic blood 
pressure and a 25 bpm  increase in heart 
rate from supine to standingNot applicable
(baseline status not 
considered)
Weight −7% increase
7% decrease
bpm = beats per minute.
aIn order to be identified as potentially clinically relevant, an on -treatment value must meet the 
“Criterion Value” and also represent a change from the subject’s baseline value of at least the 
magnitude shown in the “Change Relative to Baseline” column.
bAs defined in “Supplementary Suggestions for Preparing an Integrated Summary of Safety Information 
in an Original New Drug Application Submission and for Organizing Information in Periodic Safety 
Updates,” FDA Division of Neuropharmacological Drug Products draft (2/27/87).
Protocol 331 -201-00242
82
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202010.7 Appendix 7: Criteria for Identify ing ECG Measurements of 
Potential Clinical Relevance
Variable Criterion ValueaChange Relative to 
Baselinea
Rate
Tachycardia 120 bpm increase of 15 bpm
Bradycardia 50 bpm decrease of 15 bpm
Rhythm
Sinus tachycardiab120 bpm increase of 15 bpm
Sinus bradycardiac50 bpm decrease of 15 bpm
Supraventricular premature beat all not present present
Ventricular premature beat all not present present
Supraventricular tachycardia all not present present
Ventricular tachycardia all not present present
Atrial fibrillation all not present present
Atrial flutter all not present present
Conduction
1atrioventricular block PR 200 msec increase of 50 m sec
2atrioventricular block all not present present
3atrioventricular block all not present present
Left bundle- branch block all not present present
Right bundle -branch block all not present present
Pre-excitation syndrome all not present present
Other intraventricular conduction blockdQRS 120 msec increase of 20 m sec
Infarction
Acute or subacute all not present present
Old all not present present
12 w eeks post trial entry
ST/T Morphological
Myocardial ischemia all not present present
Symmetrical T -wave inversion all not present present
Increase in QTc QTcF > 450 msec
(males)
QTcF > 470 msec
(females)
aInorder to be identified as potentially clinically relevant, an on -treatment value must meet the 
“Criterion Value” and also represent a change from the subject’s baseline value of at least the 
magnitude shown in the “Change Relative to Baseline” column.
bNocurrent diagnosis of supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial 
flutter, or other rhythm abnormality.
cNo current diagnosis of atrial fibrillation, atrial flutter, or other rhythm abnormality.
dNo current diagnosis of left bundle branch block or right bundle branch block.
Protocol 331 -201-00242
83
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202010.8 Appendix 8: Protocol A mendments
The investigator will not make an y changes to this protocol without the sponsor’s prior 
written consent and subsequent approval/favorable opinion by  the IRB/IEC. Any 
permanent change to the protocol, whether an overall change or a change for specific trial 
site(s), must be handled as a protocol amendment. Any  amendment will be written by  the 
sponsor. Each amendment will be submitted to the I RB/IEC, as required by  local 
regulations. Exce pt for “administrative” or “non substantial” amendments, investigators 
will wait for I RB/IEC approval/favorable opinion of the amended protocol before 
implementing the change(s). Administrative amendments are defined as having no effec t 
on the safet y of subjects, conduct or management of the trial, trial design, or the quality 
or safet y of IMP(s) used in the trial. A protocol change intended to eliminate an apparent 
immediate hazard to subjects should be implemented immediately  after ag reement b y the 
sponsor and investigator, followed by  IRB/IEC notification within local applicable 
timelines. The sponsor will submit protocol amendments to the applicable regulatory  
agencies within local applicable timelines.
When the I RB/IEC, investigator s, and/or the sponsor conclude that the protocol 
amendment substantially  alters the trial design and/or increases the potential risk to the 
subject, the currently  approved written ICF will require similar modification. I n such 
cases, after approval/favorab le opinion of the new I CF by  the IRB/IEC, repeat written 
informed consent will be obtained from subjects enrolled in the trial before expecting 
continued participation and before the amendment -specified changes in the trial are 
implemented.
Protocol 331 -201-00242
86
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202011 References
1Lieb K, Zanarini MC, Schmahl C, L inehan MM, Bohus M. Borderline personality  
disorder. Lancet. 2004;364(9432) :453-61.
2Gask L, Evans M, Kessler D. Clinical review: personality  disorder. BMJ. 
2013;347(10):f5276.
3National Institute of Mental Health [homepage on the I nternet]. Bethesda: Borderline 
Personality  Disorder; Updated December 2017, Accessed 28 Aug 2018. Available 
from: http://www.nimh.nih.gov/health/topics/borderline- personality -
disorder/index.shtml.
4Grant BF, Chou SP, Goldstein RB, Huang B, Stinson FS, Saha TD, et al. Prevalence, 
correlates, disability , and comorbidity  of DSM -IV borderline personality disorder: 
results from the Wave 2 National Epidemiologic Survey  on Alcohol and Related 
Conditions. J Clin Psy chiatry . 2008;69(4):533- 545.
5Truven Marketscan Treatment Pathway s; January 2016 -December 2017, Otsuka Data 
on File.
6National Comorbidity  Survey  Replication. Biol Psy chiatry . 2007.
7American Ps ychiatric Association. Practice Guideline for the Treatment of Patients 
with Major Depressive Disorder, Third Edition. Arlington, VA: American Psy chiatric 
Association; 2010.
8Ame rican Ps ychiatric Association: Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition. Washington, DC: American Psy chiatric Association, 2013.
9Lenzenweger MF, Lane MC, L oranger AW, Kessler RC. DSM -IV personality  
disorders in the National Co morbidity  Survey  Replication. Biol Psy chiatry . 
2007;62(6):553 -564.
10Otsuka Pharmaceutical Co, L td., Otsuka Pharmaceutical Development & 
Commercialization, I nc., H. L undbeck A/S. REXUL TI® (brexpiprazole) 
Investigator's Brochure, Edition 14. Otsuka Report, issued 01 Aug 2018.
11Black DW, Zanarini MC, Romine A, Shaw M, Allen J, Schulz SC. Comparison of 
low and moderate dosages of extended- release quetiapine in borderline personality  
disorder: a randomized, double -blind, placebo -controlled trial. Am J Psy chiatry. 
2014;171(11):1174 .
12Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, et al. A dose 
comparison of olanzapine for the treatment of borderline personality  disorder: a 12-
week randomized, double -blind, placebo -controlled study . J Clin Psy chiatry. 
2011;72(10):1353 -1362.
13Schulz SC, Camlin KL , Berry  SA, Jesberger JA. Olanzapine safet y and efficacy  in 
patients with borderline personality  disorder and comorbid dy sthymia. Biol 
Psychiatry . 1999;46(10):1429-1435.
14Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, et al. 
Olanzapine for the treatment of borderline personality  disorder: variable dose 12-
week randomised double -blind placebo -controlled study . Br J Psy chiatry . 
2008;193(6):485 -492.
Protocol 331 -201-00242
87
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202015Chengappa KN, Ebeling T, Kang JS, Le vine J, Parepally  H. Clozapine reduces severe 
self-mutilation and aggression in psy chotic patients with borderline personality  
disorder. J Clin Psy chiatry . 1999;60(7):477 -484.
16Belli H, Ural C, Akbudak M.  Borderline personality  disorder:  bipolarit y, mo od 
stabilizers and aty pical antipsy chotics in treatment. J Clin Med Res. 2012;4(5):301-
308.
17Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, et al. 
Aripiprazole in the treatment of patients with borderline personality  disorder: a
double -blind, placebo -controlled study . Am J Psy chiatry . 2006;163(5):833 -838.
18Nickel MK, Loew TH, and Pedrosa Gil, F. Aripiprazole in treatment of borderline 
patients, part II: an 18 -month follow -up. Psy chopharmacology . 2007;191:1023 -1026.
19DeBellis MD, Lefter L, Trickett PK, Putnam FW. Urinary  catecholamine excretion in 
sexually  abused girls. J Am Acad Child Adol Pschiatry . 1997;33(3):320
-327.
20Friedel RO. Dopamine dy sfunction in borderline personality  disorder: a hypothesis. 
Neurops ychopharmacol. 2004;29:1029-1039.
21Joyce PR, Stephenson J, Kennedy  M, Mulder RT, McHugh PC. The presence of both 
serotonin 1A receptor (HTR1A) and dopamine transporter (DAT1) gene variants 
increase the risk of borderline personalit y disorder. Frontiers in Genetics. 
2014;4(313):1-7.
22Martin
-Blanco A, Ferrer M, Soler J, Arranz MJ, Vega D, Bauza J, et al. An 
exploratory  association study  of the influence of noradrenergic genes and childhood 
trauma in borderline personality  disorder. Ps ychiatry Research. 2015;229:589 -592.
23Oquendo MA, Mann JJ. The biology  of impulsivity  and suicidalit y. Psychiatric 
Clinics of North America. 2000;23(1):11 -25.
24Haddjeri N, de Montign y C, Blier P. Modulation of the firing activit y of 
noradrenergic neurons in the rat locus coeruleus by the 5 -hydroxy tryptamine sy stem. 
Br J Pharmacol. 1997;120:865-875.
25Skodol AE, Gunderson JG, McGlashan TH, Dy ck IR, Stout RL , Bender DS, et al. 
Functional impairment in patients with schizoty pal, borderline, avoidant, or 
obsessive -compulsive personali ty disorder. Am J Psy chiatry . 2002;159(2):276-283.
26Zanarini MC, Vujanovic AA, Parachini EA, Boulanger J L, Frankenburg FR, Hennen 
J. Zanarini rating scale for borderline personalit y disorder (ZAN -BPD): a continuous 
measure of DSM- IV borderline ps ychopath ology . J Pers Disord. 2003;17(3):233 -242.
27Guy W. ECDEU Assessment Manual for Ps ychopharmacology. US Department of 
Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National 
Institute of Mental Health; 1976.
28Lindenmay er JP, Czobo r P, Alphs L , Nathan AM, Anand R, Islam Z, et al. The 
InterSePT scale for suicidal thinking reliability  and validity . Schizophr Res. 
2003;63:161 -170.
29Larry  Alphs, personal communication.
30Üstün TB, Kostanjsek N, Chatterji S, Rehm J, editors. Measuring Health and 
Disability : Manual for WHO Disability  Assessment Schedule (WHODAS 2.0) Malta: 
World Health Organization; 2010.
Protocol 331 -201-00242
88
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul202031Üstün TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy  C, Epping -Jordan J, Saxena 
S, von Korff M, Pull C, World Health Organization. National Institutes of Health 
Developing the World Health Organization Disability  Assessment Schedule 2.0. Bull 
World Health Organ. 2010 Nov 1;88(11):815 –823.
32Zigmond AS, Snaith RP. The hospital anxiety  and depression scale. Acta Psy chiatr 
Scand. 1983; 67:361 -
370.
33First MB, Williams JBW, Benjamin LS, Spitzer RL,. User’s Guide for the SCI D-5-
PD (Structured Clinical Interview for DSM
-5 Personality  Disorder). Arlington, VA, 
American Ps ychiatric Association, 2015.
34Sheehan DV, Lecrubier Y, Harnett -Sheehan K, Amorim P, Janavs J, Weiller E, et al. 
The Mini I nternational Neurops ychiatric Interview (M.I.N.I): The development and 
validation of a structured diagnostic ps ychiatric interview for DSM -IV and ICD -10. J 
Clin Psy chiatry . 1998;59(Suppl 20):22-33.
35Sheehan DV, Lecrubier Y, Harnett- Sheehan K, Janavs J, Weiller E, Bonara LI, et al. 
The validity  of the MINI International Neurops ychiatric Interview (M.I.N. I.): 
According to the SCID -P. Eur Psy chiatry . 1997;12(5):232 -
241.
36Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. The 
MINI International Neuropsy chiatric Interview (M.I .N.I.) A short diagnostic 
structured interview: Reliability  and validity  according to the CIDI. Eur Psychiatry . 
1997;12:224 -231.
37Amorim P, Lecrubier Y, Weiller E, Hergueta T, Sheehan D. DSM -IH-R Psy chotic 
Disorders: Procedural validity  of the Mini International Neurops ychiatric Interview 
(M.I.N.I). Concordance and causes for discordance with the CIDI. Eur Ps ychiatry . 
1998;13(1):26 -34.
38The Practical Guide: Identification, evaluation, and treatment of overweight and 
obesity  in adults. Developed by National Institutes of Health National Heart, L ung 
and Blood Institute. North American Association for the Study  of Obesit y. NIH 
Publication Number 00-4084, October 2000.
39Simpson GM, Angus JW. A rating scale for extrapy ramidal side effects. Acta 
Psychiatr Scand Suppl. 1970;212(Suppl 44):S11 -
19.
40Barnes TR. A rating scale for drug -induced akathisia. Br J Psy chiatry . 1989;154:672 -
676.
41E6(R2) Go od Clinical Practice: Integrated Addendum to I CH E6(R1). Geneva, 
Switzerland: I nternational Conference on Harmonisation; 2018.
Protocol 331 -201-00242
89
Confidential -Proprietary Information Amendment 1 Approval: 0
7Jul2020Agreement
I, the undersigned principal investigator, have read and understand the protocol (including the 
Investigator's Brochure) and agree that it contains all the ethical, legal and scientific information 
necessary to conduct this trial in accordance with the principles of Good Clinical Practices and as 
described herein and in the sponsor's (or designee's) Clinical Trial Agre ement.
I will provide copies of the protocol to all physicians, nurses, and other professional personnel to 
whom I delegate trial responsibilities. I will discuss the protocol with them to ensure that they are 
sufficiently informed regarding the investiga tional new drug, OPC -34712, the concurrent medications, 
the efficacy and safety parameters and the conduct of the trial in general. I am aware that this protocol 
must be approved by the Institutional Review Board (IRB) or receive a favorable opinion by the
Independent Ethics Committee (IEC) responsible for such matters in the clinical trial facility where 
OPC -34712 will be tested prior to commencement of this trial. I agree to adhere strictly to the attached 
protocol (unless amended in the manner set forth in the sponsor's Clinical Trial Agreement, at which 
time I agree to adhere strictly to the protocol as amended).
I understand that this IRB/IEC -approved protocol will be submitted to the appropriate regulatory 
authority/ies by the sponsor. I agree that cl inical data entered on eSource by me and my staff will be 
utilized by the sponsor in various ways, such as for submission to governmental regulatory authorities 
and/or in combination with clinical data gathered from other research sites, whenever applicabl e. I 
agree to allow sponsor and designee monitors and auditors full access to all medical records at the 
research facility for subjects screened or enrolled in the trial.
I agree to await IRB/IEC approval before implementation of any substantial amendment s to this 
protocol. If, however, there is an immediate hazard to subjects, I will implement the amendment 
immediately, and provide the information to the IRB/IEC within the required local applicable 
timelines. Administrative changes to the protocol will be transmitted to the IRB/IEC for informational 
purposes only, if required by local regulations.
I agree to provide all subjects with informed consent forms, as required by the applicable regulations 
and by ICH guidelines. I agree to report to the sponsor a ny adverse experiences in accordance with the 
terms of the sponsor's Clinical Trial Agreement and the relevant regional regulation(s) and 
guideline(s). I further agree to provide all required information regarding financial certification or 
disclosure to t he sponso r for all investigators and subinvestigators in accordance with the terms of the 
relevant regional regulation(s). I understand that participation in the protocol involves a commitment 
to publish the data from this trial in a cooperative publicatio n before publication of efficacy and safety 
results on an individual basis may occur, and I consent to be acknowledged in any such cooperative 
publications that result.
____________________________ _____________________________ ___________
Principal Investigator Print Name Signature Date
T hi s p a g e i s a m a nif e st ati o n of a n el e ctr o ni c all y c a pt ur e d si g n at ur e 
SI G N A T U R E P A G E 
D o c u m e nt N a m e: 3 3 1- 2 0 1- 0 0 2 4 2 _ Pr ot o c ol A m e n d m e nt 1 
D o c u m e nt N u m b er: 1 0 0 0 0 3 4 9 9 8 
D o c u m e nt V er si o n: 4. 0 
Si g n e d b y M e a ni n g of Si g n at ur e S er v er D at e 
( d d- M M M- 
y y y y h h: mi n) - 
U T C ti m e z o n e 
Cli ni c al A p pr o v al 0 7- J ul- 2 0 2 0 
1 6: 5 3: 4 0 
A p pr o v e d f or Cli ni c al 
P h ar m a c ol o g y 
a n d N o n cli ni c al 0 7- J ul- 2 0 2 0 
1 6: 3 1: 4 7 
Bi o st ati sti c s A p pr o v al 0 7- J ul- 2 0 2 0 
1 9: 1 8: 5 3 